<SEC-DOCUMENT>0001683168-22-001925.txt : 20220324
<SEC-HEADER>0001683168-22-001925.hdr.sgml : 20220324
<ACCEPTANCE-DATETIME>20220324163949
ACCESSION NUMBER:		0001683168-22-001925
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20220324
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220324
DATE AS OF CHANGE:		20220324

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AETHLON MEDICAL INC
		CENTRAL INDEX KEY:			0000882291
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				133632859
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37487
		FILM NUMBER:		22767013

	BUSINESS ADDRESS:	
		STREET 1:		11555 SORRENTO VALLEY ROAD, SUITE 203
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-459-7800

	MAIL ADDRESS:	
		STREET 1:		11555 SORRENTO VALLEY ROAD, SUITE 203
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BISHOP EQUITIES INC
		DATE OF NAME CHANGE:	19930602
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>aethlon_i8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:AEMD="http://aethlonmedical.com/20220324">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_034_AEMD_aethlonmedical.com_20220324 -->
<!-- Field: Set; Name: xdx; ID: xdx_040_20220324_20220324 -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DEntityCentralIndexKey_0000882291 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-03-24to2022-03-24" name="dei:EntityCentralIndexKey">0000882291</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-03-24to2022-03-24" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="aemd-20220324.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-03-24to2022-03-24">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-24</xbrli:startDate>
        <xbrli:endDate>2022-03-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>FORM <span id="xdx_902_edei--DocumentType_c20220324__20220324_zGymWWNdmH8f"><ix:nonNumeric contextRef="From2022-03-24to2022-03-24" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event reported):
<span id="xdx_90A_edei--DocumentPeriodEndDate_c20220324__20220324_zHaIyARqyBN9"> <ix:nonNumeric contextRef="From2022-03-24to2022-03-24" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">March 24, 2022</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_903_edei--EntityRegistrantName_c20220324__20220324_z4WTxWtumfl4" style="font-size: 12pt"><b><ix:nonNumeric contextRef="From2022-03-24to2022-03-24" name="dei:EntityRegistrantName">AETHLON
MEDICAL, INC.</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of Registrant as Specified in Its
Charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 32%; font-size: 10pt; text-align: center"><b><span id="xdx_90B_edei--EntityIncorporationStateCountryCode_c20220324__20220324_zQ3dIexI28X8"><ix:nonNumeric contextRef="From2022-03-24to2022-03-24" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></td>
    <td style="vertical-align: bottom; width: 2%; font-size: 10pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 32%; font-size: 10pt; text-align: center"><b><span id="xdx_90B_edei--EntityFileNumber_c20220324__20220324_zXBrrZBTqUGb"><ix:nonNumeric contextRef="From2022-03-24to2022-03-24" name="dei:EntityFileNumber">001-37487</ix:nonNumeric></span></b></td>
    <td style="vertical-align: bottom; width: 2%; font-size: 10pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 32%; font-size: 10pt; text-align: center"><b><span id="xdx_908_edei--EntityTaxIdentificationNumber_c20220324__20220324_zPmIdnuqqdPd"><ix:nonNumeric contextRef="From2022-03-24to2022-03-24" name="dei:EntityTaxIdentificationNumber">13-3632859</ix:nonNumeric></span></b></td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or Other Jurisdiction</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">of Incorporation)</p></td>
    <td style="vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Commission</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">File Number)</p></td>
    <td style="vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(IRS Employer</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification No.)</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 45%">&#160;</td>
    <td style="vertical-align: bottom; width: 10%">&#160;</td>
    <td style="width: 45%">&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90C_edei--EntityAddressAddressLine1_c20220324__20220324_z4u80MiA8yKl"><ix:nonNumeric contextRef="From2022-03-24to2022-03-24" name="dei:EntityAddressAddressLine1">11555
    Sorrento Valley Road</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressAddressLine2_c20220324__20220324_zxJI9omFgSve"><ix:nonNumeric contextRef="From2022-03-24to2022-03-24" name="dei:EntityAddressAddressLine2">Suite
    203</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_905_edei--EntityAddressCityOrTown_c20220324__20220324_zInn64ugMzOd"><ix:nonNumeric contextRef="From2022-03-24to2022-03-24" name="dei:EntityAddressCityOrTown">San Diego</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressStateOrProvince_c20220324__20220324_zgyqG46mq51h"><ix:nonNumeric contextRef="From2022-03-24to2022-03-24" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span></b></p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><b><span id="xdx_90B_edei--EntityAddressPostalZipCode_c20220324__20220324_zIWNpWpZy9Da"><ix:nonNumeric contextRef="From2022-03-24to2022-03-24" name="dei:EntityAddressPostalZipCode">92121</ix:nonNumeric></span></b></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">(Address of Principal Executive Offices)</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center">(Zip Code)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Registrant&#8217;s Telephone Number, Including
Area Code: <span id="xdx_908_edei--CityAreaCode_c20220324__20220324_zDPlYrqn1r7d"><ix:nonNumeric contextRef="From2022-03-24to2022-03-24" name="dei:CityAreaCode">(619)</ix:nonNumeric></span> <span id="xdx_905_edei--LocalPhoneNumber_c20220324__20220324_zRXbAcDSywY8"><ix:nonNumeric contextRef="From2022-03-24to2022-03-24" name="dei:LocalPhoneNumber">941-0360</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>N/A </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Former Name or Former Address, if Changed Since
Last Report)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_edei--WrittenCommunications_c20220324__20220324_zQmGuxF0ZFQ"><ix:nonNumeric contextRef="From2022-03-24to2022-03-24" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_edei--SolicitingMaterial_c20220324__20220324_z3Yr2eaNbgkk"><ix:nonNumeric contextRef="From2022-03-24to2022-03-24" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_edei--PreCommencementTenderOffer_c20220324__20220324_zwWRGfZsFlma"><ix:nonNumeric contextRef="From2022-03-24to2022-03-24" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90F_edei--PreCommencementIssuerTenderOffer_c20220324__20220324_zaCgrlA1lRsi"><ix:nonNumeric contextRef="From2022-03-24to2022-03-24" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 34%; text-align: center"><b>Title of each class</b></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 31%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Trading</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Symbol(s)</b></p></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 33%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Name of each exchange</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>on which registered</b></p></td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_908_edei--Security12bTitle_c20220324__20220324_zaH7oY4InqTf"><ix:nonNumeric contextRef="From2022-03-24to2022-03-24" name="dei:Security12bTitle">Common Stock, $0.001 par value per share</ix:nonNumeric></span></b></p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><b><span id="xdx_908_edei--TradingSymbol_c20220324__20220324_zWmBqFBCCRJg"><ix:nonNumeric contextRef="From2022-03-24to2022-03-24" name="dei:TradingSymbol">AEMD</ix:nonNumeric></span></b></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><b>The <span id="xdx_90C_edei--SecurityExchangeName_c20220324__20220324_zddTS2vGKnR1"><ix:nonNumeric contextRef="From2022-03-24to2022-03-24" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (&#167; 240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_edei--EntityEmergingGrowthCompany_c20220324__20220324_zb5oCsEOqnTg"><ix:nonNumeric contextRef="From2022-03-24to2022-03-24" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 11%; font-size: 10pt"><span style="font-size: 10pt"><b>Item 1.01</b></span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt"><b>Entry into a Material Definitive Agreement. </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 24, 2022, Aethlon Medical, Inc. (&#8220;we,&#8221; &#8220;us,&#8221;
or &#8220;our&#8221;) entered into an At the Market Offering Agreement (the &#8220;Offering Agreement&#8221;) with H.C. Wainwright &amp;
Co., LLC, as sales agent (&#8220;Wainwright&#8221;), pursuant to which we may offer and sell shares of our common stock, par value $0.001
per share (the &#8220;Common Stock&#8221;), from time to time through Wainwright.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The offering has been registered under the Securities Act of 1933,
as amended, pursuant to the Company&#8217;s shelf registration statement on S-3 (Registration Statement No. 333-259909), as previously
filed with the Securities and Exchange Commission and declared effective on October 21, 2021. We filed a prospectus supplement, dated
March 24, 2022, with the Securities and Exchange Commission in connection with the offer and sale of the shares of Common Stock, pursuant
to which the Company may offer and sell shares of Common Stock having an aggregate offering price of up to $15,000,000 from time to time
through Wainwright (the &#8220;Shares&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the Offering Agreement, Wainwright may sell the Shares by any
method permitted by law and deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415 promulgated under the Securities
Act of 1933, as amended (the &#8220;Securities Act&#8221;), including sales made directly on the Nasdaq Capital Market, or on any other
existing trading market for the Shares. In addition, under the Offering Agreement, Wainwright may sell the Shares in privately negotiated
transactions with our consent and in block transactions. Under certain circumstances, we may instruct Wainwright not to sell the Shares
if the sales cannot be effected at or above the price designated by us from time to time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are not obligated to make any sales of the Shares under the Offering
Agreement. The offering of the Shares pursuant to the Offering Agreement will terminate upon the termination of the Offering Agreement
by Wainwright or us, as permitted therein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Offering Agreement contains customary representations, warranties
and agreements by us, and customary indemnification and contribution rights and obligations of the parties. We agreed to pay Wainwright
a placement fee of up to 3.0% of the aggregate gross proceeds from each sale of the Shares. We also agreed to reimburse Wainwright for
certain specified expenses in connection with entering into the Offering Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Offering Agreement is filed as Exhibit 1.1 to this Current Report
on Form 8-K, and the description of the terms of the Offering Agreement is qualified in its entirety by reference to such exhibit. A copy
of the opinion of Brownstein Hyatt Farber Schreck, LLP relating to the issuance and sale of the Shares pursuant to the Offering Agreement
is attached as Exhibit 5.1 hereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Current Report on Form 8-K shall not constitute an offer to sell
or the solicitation of an offer to buy the securities discussed herein, nor shall there be any offer, solicitation, or sale of the securities
in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws
of any such state.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9.01 Financial Statements and Exhibits. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>(d) Exhibits. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b>Exhibit<br />
No.</b></span></td>
    <td style="width: 4%">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center; width: 93%"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-size: 10pt">1.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-size: 10pt"><a href="aethlon_ex0101.htm">At the Market Offering Agreement, dated March 24, 2022, by and between Aethlon Medical, Inc. and H.C. Wainwright &amp; Co., LLC</a>.</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-size: 10pt">5.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-size: 10pt"><a href="aethlon_ex0501.htm">Opinion of Brownstein Hyatt Farber Schreck, LLP</a>.</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-size: 10pt">23.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-size: 10pt">Consent of Brownstein Hyatt Farber Schreck, LLP (contained in <a href="aethlon_ex0501.htm">Exhibit 5.1</a>). </span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt">&#160;</td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt"><span style="font-size: 10pt">104</span></td>
    <td style="vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-size: 10pt">Date: March 24, 2022</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="3" style="vertical-align: bottom; font-size: 10pt"><span style="font-size: 10pt"><b>Aethlon Medical, Inc.</b></span></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td rowspan="3" style="vertical-align: top; width: 49%">&#160;</td>
    <td rowspan="3" style="vertical-align: bottom; width: 0%">&#160;</td>
    <td rowspan="3" style="vertical-align: bottom; width: 4%">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; width: 6%"><span style="font-size: 10pt">By:</span></td>
    <td style="vertical-align: bottom; width: 0%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font-size: 10pt; width: 37%"><span style="font-size: 10pt">/s/ James B. Frakes</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Name:</span></td>
    <td>&#160;</td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">James B. Frakes</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="font-size: 10pt"><span style="font-size: 10pt"><i>Chief Financial Officer</i></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6LbMb+MMuHSrilDFEvC0uk+LWjLRO90i+pXVDDIGQnPPlCDERW9roGhkuqyKDEzZtrRxCgRUymit6R7rbJ+BngTdtHSvjhvUHpuQZ9MwsXCh/H5ydtlgmIJdTOZ/GEcg4mUnIDyL46imZSpdonFY1KFNCztSyRqe4Hz+c1IsMNf2QdEa2mkwCUShH+Q2xjGI4UqeexHcLWZaKYDJUILZMj/Yb87COGljX2PgsO6L/Dj7fLUkb -->


</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>aethlon_ex0101.htm
<DESCRIPTION>AT THE MARKET OFFERING AGREEMENT, DATED MARCH 24, 2022, BY AND BETWEEN AETHLON MEDICAL, INC. AND H.C. WAINWRIGHT & CO., LLC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 1.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AT THE MARKET OFFERING AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.5in; text-align: justify">March 24, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">H.C. Wainwright &amp; Co., LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">430 Park Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0; text-align: justify">New York, New York 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0.5in; text-align: justify; text-indent: -0.5in">Ladies and
Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0.5in; text-align: justify; text-indent: 0.25in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Aethlon Medical, Inc., a corporation
organized under the laws of Nevada (the &ldquo;<U>Company</U>&rdquo;), confirms its agreement (this &ldquo;<U>Agreement</U>&rdquo;) with
H.C. Wainwright &amp; Co., LLC (the &ldquo;<U>Manager</U>&rdquo;) as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8239;&nbsp;&nbsp;&nbsp;
</FONT><U>Definitions</U>. The terms that follow, when used in this Agreement and any Terms Agreement, shall have the meanings indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Accountants</U>&rdquo;&nbsp;shall
have the meaning ascribed to such term in Section 4(m).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Act</U>&rdquo;
shall mean the Securities Act of 1933, as amended, and the rules and regulations of the Commission promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section 3(k).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
shall have the meaning ascribed to such term in Section 3(j).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Applicable
Time</U>&rdquo; shall mean, with respect to any Shares, the time of sale of such Shares pursuant to this Agreement or any relevant Terms
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Base Prospectus</U>&rdquo;
shall mean the base prospectus contained in the Registration Statement at the Execution Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board</U>&rdquo;
shall have the meaning ascribed to such term in Section 2(b)(iii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Broker
Fee</U>&rdquo; shall have the meaning ascribed to such term in Section 2(b)(v).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; shall mean any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, that, for purposes of clarity, commercial banks shall not be deemed
to be authorized or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential
employee&rdquo;&nbsp; or any other similar orders or restrictions or the closure of any physical branch locations at the direction of
any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The
City of New York generally are open for use by customers on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
shall mean the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock</U>&rdquo; shall have the meaning ascribed to such term in Section 2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; shall have the meaning ascribed to such term in Section 3(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company
Counsel</U>&rdquo; shall have the meaning ascribed to such term in Section 4(l).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>DTC</U>&rdquo;
shall have the meaning ascribed to such term in Section 2(b)(vii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Effective
Date</U>&rdquo; shall mean each date and time that the Registration Statement and any post-effective amendment or amendments thereto became
or becomes effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Environmental
Laws</U>&rdquo; shall have the meaning ascribed to such term in Section 3(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; shall mean the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission promulgated
thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Execution
Time</U>&rdquo; shall mean the date and time that this Agreement is executed and delivered by the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Free Writing
Prospectus</U>&rdquo; shall mean a free writing prospectus, as defined in Rule&nbsp;405.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section 3(n).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Hazardous
Materials</U>&rdquo; shall have the meaning ascribed to such term in Section 3(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Incorporated
Documents</U>&rdquo; shall mean the documents or portions thereof filed with the Commission on or prior to the Effective Date that are
incorporated by reference in the Registration Statement or the Prospectus and any documents or portions thereof filed with the Commission
after the Effective Date that are deemed to be incorporated by reference in the Registration Statement or the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in Section 3(p).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Issuer
Free Writing Prospectus</U>&rdquo; shall mean an issuer free writing prospectus, as defined in Rule&nbsp;433.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Losses</U>&rdquo;
shall have the meaning ascribed to such term in Section 7(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning ascribed to such term in Section 3(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Permits</U>&rdquo; shall have the meaning ascribed to such term in Section 3(n).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Maximum
Amount</U>&rdquo; shall have the meaning ascribed to such term in Section 2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Net Proceeds</U>&rdquo;
shall have the meaning ascribed to such term in Section 2(b)(v).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Permitted
Free Writing Prospectus</U>&rdquo; shall have the meaning ascribed to such term in Section 4(g).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Placement</U>&rdquo;
shall have the meaning ascribed to such term in Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Proceeding</U>&rdquo;
shall have the meaning ascribed to such term in Section 3(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prospectus</U>&rdquo;
shall mean the Base Prospectus, as supplemented by the most recently filed Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prospectus
Supplement</U>&rdquo; shall mean each prospectus supplement relating to the Shares prepared and filed pursuant to Rule&nbsp;424(b) from
time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration
Statement</U>&rdquo; shall mean the shelf registration statement (File Number&nbsp;333-259909) on Form&nbsp;S-3, including exhibits and
financial statements and any prospectus supplement relating to the Shares that is filed with the Commission pursuant to Rule&nbsp;424(b)
and deemed part of such registration statement pursuant to Rule&nbsp;430B, as amended on each Effective Date and, in the event any post-effective
amendment thereto becomes effective, shall also mean such registration statement as so amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Representation
Date</U>&rdquo; shall have the meaning ascribed to such term in Section 4(k).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section 3(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule&nbsp;158</U>&rdquo;,
&ldquo;<U>Rule&nbsp;164</U>&rdquo;, &ldquo;<U>Rule&nbsp;172</U>&rdquo;, &ldquo;<U>Rule&nbsp;173</U>&rdquo;, &ldquo;<U>Rule&nbsp;405</U>&rdquo;,
&ldquo;<U>Rule&nbsp;415</U>&rdquo;, &ldquo;<U>Rule&nbsp;424</U>&rdquo;, &ldquo;<U>Rule&nbsp;430B</U>&rdquo; and &ldquo;<U>Rule&nbsp;433</U>&rdquo;
refer to such rules under the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Sales
Notice</U>&rdquo; shall have the meaning ascribed to such term in Section 2(b)(i).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>SEC Reports</U>&rdquo;
shall have the meaning ascribed to such term in Section 3(i).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Settlement
Date</U>&rdquo; shall have the meaning ascribed to such term in Section 2(b)(vii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Shares</U>&rdquo;
shall have the meaning ascribed to such term in Section 2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
shall have the meaning ascribed to such term in Section 3(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Terms
Agreement</U>&rdquo; shall have the meaning ascribed to such term in Section 2(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Time of
Delivery</U>&rdquo; shall have the meaning ascribed to such term in Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means the Nasdaq Capital Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Sale and Delivery of Shares</U>. The Company proposes to issue and sell through or to the Manager, as sales agent and/or principal,
from time to time during the term of this Agreement and on the terms set forth herein, up to the lesser of such number of shares (the
&ldquo;<U>Shares</U>&rdquo;) of the Company&rsquo;s common stock, $0.001&nbsp;par value per share (&ldquo;<U>Common Stock</U>&rdquo;),
that does not exceed (a) the number or dollar amount of shares of Common Stock registered on the Registration Statement, pursuant to which
the offering is being made, (b) the number of then authorized but unissued shares of Common Stock (less the number of shares of Common
Stock then issuable pursuant to any outstanding options, warrants, convertible securities or other rights, agreements (other than this
Agreement), plans, arrangements or commitments of the Company or otherwise, and including any and all shares of Common Stock then reserved
for issuance (other than pursuant to this Agreement)), or (c) the number or dollar amount of shares of Common Stock that would cause the
Company or the offering of the Shares to not satisfy the eligibility and transaction requirements for use of Form S-3, including, if applicable,
General Instruction I.B.6 of Registration Statement on Form S-3 (the lesser of (a), (b) and (c), the &ldquo;<U>Maximum Amount</U>&rdquo;).
Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitations set forth in
this Section 2 on the number and aggregate sales price of Shares issued and sold under this Agreement shall be the sole responsibility
of the Company and that the Manager shall have no obligation in connection with such compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Appointment of Manager as Selling Agent; Terms Agreement</U>. For purposes of selling the Shares through the Manager, the Company
hereby appoints the Manager as exclusive agent of the Company for the purpose of selling the Shares of the Company pursuant to this Agreement
and the Manager agrees to use its commercially reasonable efforts to sell the Shares on the terms and subject to the conditions stated
herein. The Company agrees that, whenever it determines to sell the Shares directly to the Manager as principal, it will enter into a
separate agreement (each, a &ldquo;<U>Terms Agreement</U>&rdquo;) in substantially the form of <U>Annex I</U> hereto, relating to such
sale in accordance with Section&nbsp;2 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Agent Sales</U>. Subject to the terms and conditions and in reliance upon the representations and warranties herein set forth,
the Company will issue and agrees to sell Shares from time to time through the Manager, acting as sales agent, and the Manager agrees
to use its commercially reasonable efforts to sell, as sales agent for the Company, on the following terms:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Shares are to be sold on a daily basis or otherwise as shall be agreed to by the Company and the Manager on any day that (A)&nbsp;is
a Trading Day, (B)&nbsp;the Company has instructed the Manager by telephone (confirmed promptly by electronic mail) to make such sales
(&ldquo;<U>Sales Notice</U>&rdquo;) and (C) the Company has satisfied its obligations under Section 6 of this Agreement. The Company will
designate the maximum amount of the Shares to be sold by the Manager daily (subject to the limitations set forth in Section 2(d)) and
the minimum price per Share at which such Shares may be sold. Subject to the terms and conditions hereof, the Manager shall use its commercially
reasonable efforts to sell on a particular day all of the Shares designated for the sale by the Company on such day. The gross sales price
of the Shares sold under this Section&nbsp;2(b) shall be the market price for the shares of Common Stock sold by the Manager under this
Section&nbsp;2(b) on the Trading Market at the time of sale of such Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company acknowledges and agrees that (A)&nbsp;there can be no assurance that the Manager will be successful in selling the
Shares, (B)&nbsp;the Manager will incur no liability or obligation to the Company or any other person or entity if it does not sell the
Shares for any reason other than a failure by the Manager to use its commercially reasonable efforts consistent with its normal trading
and sales practices and applicable law and regulations to sell such Shares as required under this Agreement, and (C)&nbsp;the Manager
shall be under no obligation to purchase Shares on a principal basis pursuant to this Agreement, except as otherwise specifically agreed
by the Manager and the Company pursuant to a Terms Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company shall not authorize the issuance and sale of, and the Manager shall not be obligated to use its commercially reasonable
efforts to sell, any Share at a price that is lower than the minimum price therefor designated from time to time by the Company&rsquo;s
Board of Directors (the &ldquo;<U>Board</U>&rdquo;), or a duly authorized committee thereof, or such duly authorized officers of the Company,
and notified to the Manager in writing. The Company or the Manager may, upon notice to the other party hereto by telephone (confirmed
promptly by electronic mail), suspend the offering of the Shares for any reason and at any time; <U>provided</U>, <U>however</U>, that
such suspension or termination shall not affect or impair the parties&rsquo; respective obligations with respect to the Shares sold hereunder
prior to the giving of such notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Manager may sell Shares by any method permitted by law deemed to be an &ldquo;at the market offering&rdquo; as defined in Rule&nbsp;415
under the Act, including without limitation sales made directly on the Trading Market, on any other existing trading market for the Common
Stock or to or through a market maker. The Manager may also sell Shares in privately negotiated transactions, provided that the Manager
receives the Company&rsquo;s prior written approval for any sales in privately negotiated transactions and if so provided in the &ldquo;Plan
of Distribution&rdquo; section of the Prospectus Supplement or a supplement to the Prospectus Supplement or a new Prospectus Supplement
disclosing the terms of such privately negotiated transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The compensation to the Manager for sales of the Shares under this Section 2(b) shall be a placement fee of up to 3.0% of the gross
sales price of the Shares sold pursuant to this Section 2(b) (&ldquo;<U>Broker Fee</U>&rdquo;). The foregoing rate of compensation shall
not apply when the Manager acts as principal, in which case the Company may sell Shares to the Manager as principal at a price agreed
upon at the relevant Applicable Time pursuant to a Terms Agreement. The remaining proceeds, after deduction of the Broker Fee and deduction
of any transaction fees imposed by any clearing firm, execution broker, or governmental or self-regulatory organization in respect of
such sales, shall constitute the net proceeds to the Company for such Shares (the &ldquo;<U>Net Proceeds</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Manager shall provide written confirmation (which may be by facsimile or electronic mail) to the Company following the close
of trading on the Trading Market each day in which the Shares are sold under this Section 2(b) setting forth the number of the Shares
sold on such day, the aggregate gross sales proceeds and the Net Proceeds to the Company, and the compensation payable by the Company
to the Manager with respect to such sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Unless otherwise agreed between the Company and the Manager, settlement for sales of the Shares will occur at 10:00 a.m. (New York
City time) on the second (2nd) Trading Day (or such earlier day as is industry practice for regular-way trading) following the date on
which such sales are made (each, a &ldquo;<U>Settlement Date</U>&rdquo;). On or before the Trading Day prior to each Settlement Date,
the Company will, or will cause its transfer agent to, electronically transfer the Shares being sold by crediting the Manager&rsquo;s
or its designee&rsquo;s account (provided that the Manager shall have given the Company written notice of such designee at least one Trading
Day prior to the Settlement Date) at The Depository Trust Company (&ldquo;<U>DTC</U>&rdquo;) through its Deposit and Withdrawal at Custodian
System or by such other means of delivery as may be mutually agreed upon by the parties hereto which Shares in all cases shall be freely
tradable, transferable, registered shares in good deliverable form. On each Settlement Date, the Manager will deliver the related Net
Proceeds in same day funds to an account designated by the Company. The Company agrees that, if the Company, or its transfer agent (if
applicable), defaults in its obligation to deliver duly authorized Shares on a Settlement Date, in addition to and in no way limiting
the rights and obligations set forth in Section 7 hereto, the Company will (i) hold the Manager harmless against any loss, claim, damage,
or reasonable, documented expense (including reasonable and documented legal fees and expenses), as incurred, arising out of or in connection
with such default by the Company, and (ii) pay to the Manager any commission, discount or other compensation to which the Manager would
otherwise have been entitled absent such default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(viii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>At each Applicable Time, Settlement Date and Representation Date, the Company shall be deemed to have affirmed each representation
and warranty contained in this Agreement as if such representation and warranty were made as of such date (except to the extent that any
such representation or warranty is made as of a specified date, in which case such representation or warranty shall have been true and
correct as of such date), modified as necessary to relate to the Registration Statement and the Prospectus as amended as of such date.
Any obligation of the Manager to use its commercially reasonable efforts to sell the Shares on behalf of the Company shall be subject
to the continuing accuracy of the representations and warranties of the Company herein, to the performance by the Company of its obligations
hereunder and to the continuing satisfaction of the additional conditions specified in Section 6 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders
of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or
other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement
or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo; and the record date for the determination of stockholders entitled
to receive the Distribution, the &ldquo;<U>Record Date</U>&rdquo;), the Company hereby covenants that, in connection with any sales of
Shares pursuant to a Sales Notice on the Record Date, the Company covenants and agrees that the Company shall issue and deliver such Shares
to the Manager on the Record Date and the Record Date shall be the Settlement Date and the Company shall cover any additional costs of
the Manager in connection with the delivery of Shares on the Record Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Term Sales</U>. If the Company wishes to sell the Shares pursuant to this Agreement but other than as set forth in Section 2(b)
of this Agreement (each, a &ldquo;<U>Placement</U>&rdquo;), the Company will notify the Manager of the proposed terms of such Placement.
If the Manager, acting as principal, wishes to accept such proposed terms (which it may decline to do for any reason in its sole discretion)
or, following discussions with the Company wishes to accept amended terms, the Manager and the Company will enter into a Terms Agreement
setting forth the terms of such Placement. The terms set forth in a Terms Agreement will not be binding on the Company or the Manager
unless and until the Company and the Manager have each executed such Terms Agreement accepting all of the terms of such Terms Agreement.
In the event of a conflict between the terms of this Agreement and the terms of a Terms Agreement, the terms of such Terms Agreement will
control. A Terms Agreement may also specify certain provisions relating to the reoffering of such Shares by the Manager. The commitment
of the Manager to purchase the Shares pursuant to any Terms Agreement shall be deemed to have been made on the basis of the representations
and warranties of the Company herein contained and shall be subject to the terms and conditions herein set forth. Each Terms Agreement
shall specify the number of the Shares to be purchased by the Manager pursuant thereto, the price to be paid to the Company for such Shares,
any provisions relating to rights of, and default by, underwriters acting together with the Manager in the reoffering of the Shares, and
the time and date (each such time and date being referred to herein as a &ldquo;<U>Time of Delivery</U>&rdquo;) and place of delivery
of and payment for such Shares. Such Terms Agreement shall also specify any requirements for opinions of counsel, accountants&rsquo; letters
and officers&rsquo; certificates pursuant to Section 6 of this Agreement and any other information or documents required by the Manager.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Maximum Number of Shares</U>. Under no circumstances shall the Company cause or request the offer or sale of any Shares if,
after giving effect to the sale of such Shares, the aggregate amount of Shares sold pursuant to this Agreement would exceed the lesser
of (A) together with all prior sales of Shares under this Agreement, the Maximum Amount, (B) the amount available for offer and sale under
the currently effective Registration Statement and (C) the amount authorized from time to time to be issued and sold under this Agreement
pursuant to resolution of the Board, a duly authorized committee thereof or a duly authorized executive committee, and notified to the
Manager in writing. Under no circumstances shall the Company cause or request the offer or sale of any Shares pursuant to this Agreement
at a price lower than the minimum price authorized from time to time pursuant to resolution of the Board, a duly authorized committee
thereof or a duly authorized executive officer, and notified to the Manager in writing. Further, under no circumstances shall the Company
cause or permit the aggregate offering amount of Shares sold pursuant to this Agreement to exceed the Maximum Amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Regulation M Notice</U>. Unless the exceptive provisions set forth in Rule&nbsp;101(c)(1) of Regulation&nbsp;M under the Exchange
Act are satisfied with respect to the Shares, the Company shall give the Manager at least one Business Day&rsquo;s prior notice of its
intent to sell any Shares in order to allow the Manager time to comply with Regulation M.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Representations and Warranties</U>. The Company represents and warrants to, and agrees with, the Manager at the Execution Time
and on each such time the following representations and warranties are repeated or deemed to be made pursuant to this Agreement, as set
forth below, except to the extent set forth in the Registration Statement, the Prospectus or the Incorporated Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Subsidiaries</U>. All of the direct and indirect subsidiaries (individually, a &ldquo;<U>Subsidiary</U>&rdquo;) of the Company
are set forth in the SEC Reports. Except as set forth in the SEC Reports, the Company owns, directly or indirectly, all of the capital
stock or other equity interests of each Subsidiary free and clear of any &ldquo;<U>Liens</U>&rdquo; (which for purposes of this Agreement
shall mean a lien, charge, security interest, encumbrance, right of first refusal, preemptive right or other restriction). All of the
issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive
and similar rights to subscribe for or purchase securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Organization and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized,
validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power
and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any
Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or
other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good
standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned
by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not
have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of this Agreement,
(ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the
Company and the Subsidiaries, taken as a whole, from that set forth in the Registration Statement, the Base Prospectus, any Prospectus
Supplement, the Prospectus or the Incorporated Documents, or (iii) a material adverse effect on the Company&rsquo;s ability to perform
in any material respect on a timely basis its obligations under this Agreement (any of (i), (ii) or (iii), a &ldquo;<U>Material Adverse
Effect</U>&rdquo;) and no &ldquo;<U>Proceeding</U>&rdquo; (which for purposes of this Agreement shall mean any action, claim, suit, investigation
or proceeding (including, without limitation, an informal investigation or partial proceeding, such as a deposition), whether commenced
or threatened) has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such
power and authority or qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Authorization and Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate
the transactions contemplated by this Agreement and otherwise to carry out its obligations hereunder. The execution and delivery of this
Agreement by the Company and the consummation by it of the transactions contemplated hereby have been duly authorized by all necessary
action on the part of the Company and no further action is required by the Company, the Board or the Company&rsquo;s stockholders in connection
herewith other than in connection with the Required Approvals. This Agreement has been (or upon delivery will have been) duly executed
and delivered by the Company and, when delivered in accordance with the terms hereof, will constitute the valid and binding obligation
of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and
applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&rsquo;
rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies,
and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Conflicts</U>. The execution, delivery and performance by the Company of this Agreement, the issuance and sale of the Shares
and the consummation by it of the transactions contemplated hereby do not and will not (i) conflict with or violate any provision of the
Company&rsquo;s or any Subsidiary&rsquo;s certificate or articles of incorporation, bylaws or other organizational or charter documents,
or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result
in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination,
amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other
instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party
or by which any property or asset of the Company or any Subsidiary is bound or affected or, except as disclosed in the SEC Reports, to
give to others any rights of anti-dilution or similar adjustments on any agreement, credit facility, debt or other instrument to which
the Company or any Subsidiary is a party, or (iii) subject to the Required Approvals, conflict with or result in a violation of any law,
rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company
or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company
or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected
to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Filings, Consents and Approvals.</U> The Company is not required to obtain any consent, waiver, authorization or order of, give
any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other
&ldquo;Person&rdquo; (defined as an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture,
limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind, including
the Trading Market) in connection with the execution, delivery and performance by the Company of this Agreement, other than (i) the filings
required by this Agreement, (ii) the filing with the Commission of the Prospectus Supplement, (iii) the filing of application(s) to and
approval by the Trading Market for the listing of the Shares for trading thereon in the time and manner required thereby, and (iv) such
filings as are required to be made under applicable state securities laws and the rules and regulations of the Financial Industry Regulatory
Authority, Inc. (&ldquo;<U>FINRA</U>&rdquo;) (collectively, the &ldquo;<U>Required Approvals</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Registration Statement</U>. The Company meets the requirements for use of Form&nbsp;S-3 under the Act and has prepared and filed
with the Commission the Registration Statement, including a related Base Prospectus, for registration under the Act of the offering and
sale of the Shares. Such Registration Statement is effective and available for the offer and sale of the Shares as of the date hereof.
As filed, the Base Prospectus contains all information required by the Act and the rules thereunder, and, except to the extent the Manager
shall agree in writing to a modification, shall be in all substantive respects in the form furnished to the Manager prior to the Execution
Time or prior to any such time this representation is repeated or deemed to be made. The Registration Statement, at the Execution Time,
each such time this representation is repeated or deemed to be made, and at all times during which a prospectus is required by the Act
to be delivered (whether physically or through compliance with Rule&nbsp;172, 173 or any similar rule) in connection with any offer or
sale of the Shares, meets the requirements set forth in Rule&nbsp;415(a)(1)(x). The initial Effective Date of the Registration Statement
was not earlier than the date three years before the Execution Time. The Company meets the transaction requirements with respect to the
aggregate market value of securities being sold pursuant to this offering and during the twelve (12) months prior to this offering, as
set forth in General Instruction I.B.6 of Form S-3, if applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Issuance of Shares</U>. The Shares are duly authorized and, when issued and paid for in accordance with this Agreement, will
be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Company has reserved
from its duly authorized capital stock a sufficient number of shares of Common Stock issuable pursuant to this Agreement. The Shares are
not and will not be subject to the preemptive rights of any holders of any security of the Company or similar contractual rights granted
by the Company. All corporate action required to be taken for the authorization, issuance and sale of the Shares has been duly and validly
taken. The Shares conform in all material respects to all statements with respect thereto contained in the Prospectus. The &ldquo;<U>Plan
of Distribution</U>&rdquo; section within the Registration Statement permits the issuance and sale of the Shares as contemplated by this
Agreement. Upon receipt of the Shares, the purchasers of such Shares will have good and marketable title to such Shares and the Shares
will be freely tradable on the Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Capitalization</U>. The capitalization of the Company is as set forth in the SEC Reports. The Company has not issued any capital
stock since its most recently filed periodic report under the Exchange Act, other than pursuant to the exercise of employee stock options
and the vesting of restricted stock awards under the Company&rsquo;s equity incentive plans, the issuance of shares of Common Stock or
stock options to employees pursuant to the Company&rsquo;s equity incentive plans, and pursuant to the conversion and/or exercise of securities
exercisable, exchangeable or convertible into Common Stock (&ldquo;<U>Common Stock Equivalents</U>&rdquo;) outstanding as of the date
of the most recently filed periodic report under the Exchange Act. No Person has any right of first refusal, preemptive right, right of
participation, or any similar right to participate in the transactions contemplated by this Agreement. Except as set forth in the SEC
Reports or provided by this Agreement, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments
of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or
giving any Person any right to subscribe for or acquire, any shares of Common Stock, or contracts, commitments, understandings or arrangements
by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or
capital stock of any Subsidiary. The issuance and sale of the Shares will not obligate the Company to issue shares of Common Stock or
other securities to any Person. Except as set forth in the SEC Reports, there are no outstanding securities or instruments of the Company
or any Subsidiary with any provision that adjusts the exercise, conversion, exchange or reset price of such security or instrument upon
an issuance of securities by the Company or any Subsidiary. Except as set forth in the SEC Reports, there are no outstanding securities
or instruments of the Company or any Subsidiary that contain any redemption or similar provisions, and there are no contracts, commitments,
understandings or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such
Subsidiary. Except as set forth in the SEC Reports, the Company does not have any stock appreciation rights or &ldquo;phantom stock&rdquo;
plans or agreements or any similar plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized,
validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none of such
outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. No further
approval or authorization of any stockholder, the Board or others is required for the issuance and sale of the Shares. There are no stockholders
agreements, voting agreements or other similar agreements with respect to the Company&rsquo;s capital stock to which the Company is a
party or, to the knowledge of the Company, between or among any of the Company&rsquo;s stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>SEC Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required
to be filed by the Company under the Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two years
preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing
materials, including the exhibits thereto and documents incorporated by reference therein, together with the Prospectus and the Prospectus
Supplement, being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;) on a timely basis or has received a valid extension
of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates,
the SEC Reports complied in all material respects with the requirements of the Act and the Exchange Act, as applicable, and none of the
SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein
or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The
financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements
and the rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have
been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods
involved (&ldquo;<U>GAAP</U>&rdquo;), except as may be otherwise specified in such financial statements or the notes thereto and except
that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial
position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows
for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Material Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements
included within the SEC Reports, except as specifically disclosed in a subsequent SEC Report filed prior to the date on which this representation
is being made, (i) there has been no event, occurrence or development that has had or that could reasonably be expected to result in a
Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and
accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected
in the Company&rsquo;s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company has not
altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other property to
its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock, (v) the Company
has not issued any equity securities to any officer, director or &ldquo;<U>Affiliate</U>&rdquo; (defined as any Person that, directly
or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms
are used in and construed under Rule 144 under the Act), except pursuant to existing Company stock option plans and (vi) no officer or
director of the Company has resigned from any position with the Company. The Company does not have pending before the Commission any request
for confidential treatment of information. Except for the issuance of the Shares contemplated by this Agreement, no event, liability,
fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company
or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition that would be required
to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed made that has not been
publicly disclosed at least one Trading Day prior to the date that this representation is made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Litigation</U>. Except as set forth in the SEC Reports, there is no action, suit, inquiry, notice of violation, proceeding or
investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their
respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state,
county, local or foreign) (collectively, an &ldquo;<U>Action</U>&rdquo;) which (i) adversely affects or challenges the legality, validity
or enforceability of this Agreement or the Shares or (ii) could, if there were an unfavorable decision, have or reasonably be expected
to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor any director or officer thereof, is or has been the
subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary
duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission
involving the Company or any current or former director or officer of the Company. The Commission has not issued any stop order or other
order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Labor Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees
of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo;
employees is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither the
Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that
their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary,
is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary
information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third
party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability
with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local and
foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours,
except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compliance</U>. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred
that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under),
nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture,
loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound
(whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator
or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental
authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational
health and safety, product quality and safety and employment and labor matters, except in each case as could not have or reasonably be
expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Regulatory Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the
appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the
SEC Reports, except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect
(&ldquo;<U>Material Permits</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to
the revocation or modification of any Material Permit. The disclosures in the Prospectus concerning the effects of Federal, State, local
and all foreign regulation on the Company&rsquo;s business as currently contemplated are correct in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(o)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Title to Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to, or have valid and marketable
rights to lease or otherwise use, all real property and all personal property owned by them that is material to the business of the Company
and the Subsidiaries, in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property
and do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii)
Liens for the payment of federal, state or other taxes, for which appropriate reserves have been made in accordance with GAAP and, the
payment of which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and
the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(p)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Intellectual Property</U>. To the best of the Company&rsquo;s knowledge, the Company and the Subsidiaries have, or have rights
to make, have made, use, have used, sell, offer to sell, import and/or export all technologies related to patents, patent applications,
trademarks, trademark applications, service marks, trade names, trade secrets, inventions, know-how, show-how, copyrights, licenses and
other intellectual property rights and similar rights owned or licensed by Company and necessary or required for use in connection with
their respective businesses as described in the SEC Reports and which the failure to do so could have a Material Adverse Effect (collectively,
the &ldquo;<U>Intellectual Property Rights</U>&rdquo;). None of, and neither the Company nor any Subsidiary has received a notice (written
or otherwise) that any of, the Intellectual Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate
or be abandoned, within two (2) years from the date of this Agreement, except for patents that will expire within two years from the date
of this Agreement. Neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements included
within the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe
upon the rights of any Person. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no
existing infringement by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable
security measures to protect the secrecy, confidentiality and value of all of their intellectual properties, except where failure to do
so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(q)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Insurance</U>. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such
losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged,
including, but not limited to, directors and officers insurance coverage. Neither the Company nor any Subsidiary has any reason to believe
that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from
similar insurers as may be necessary to continue its business without a significant increase in cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(r)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Transactions With Affiliates and Employees</U>. Except as set forth in the SEC Reports, none of the officers or directors of
the Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently
a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including
any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal
property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer,
director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial
interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i) payment
of salary or consulting or director fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company, and
(iii) other employee benefits, including stock option agreements and restricted stock awards under any stock option plan of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(s)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Sarbanes Oxley Compliance</U>. The Company and the Subsidiaries are in compliance with any and all applicable requirements of
the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable rules and regulations promulgated
by the Commission thereunder that are effective as of the date hereof. The Company and the Subsidiaries maintain a system of internal
accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management&rsquo;s
general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity
with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management&rsquo;s general
or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals
and appropriate action is taken with respect to any differences. The Company and the Subsidiaries have established disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure
controls and procedures to ensure that information required to be disclosed by the Company in the reports it files or submits under the
Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&rsquo;s rules and forms.
The Company&rsquo;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and
the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date, the
&ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented in its most recently filed periodic report under the Exchange Act the conclusions
of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation
Date. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as such term is defined
in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely to materially affect,
the internal control over financial reporting of the Company and its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(t)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Certain Fees</U>. Other than payments to be made to the Manager, no brokerage or finder&rsquo;s fees or commissions are or will
be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker,
bank or other Person with respect to the transactions contemplated by this Agreement. The Manager shall have no obligation with respect
to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may
be due in connection with the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(u)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Listing and Maintenance Requirements</U>. The Common Stock is listed on the Trading Market and the issuance of the Shares as
contemplated by this Agreement does not contravene the rules and regulations of the Trading Market. The Common Stock is registered pursuant
to Section 12(b) or 12(g) of the Exchange Act, and the Company has taken no action designed to, or which to its knowledge is likely to
have the effect of, terminating the registration of the Common Stock under the Exchange Act nor has the Company received any notification
that the Commission is contemplating terminating such registration. The Company has not, in the 12 months preceding the date hereof, received
notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance
with the listing or maintenance requirements of such Trading Market. The Company is, and has no reason to believe that it will not in
the foreseeable future continue to be, in compliance with all such listing and maintenance requirements. The Common Stock is currently
eligible for electronic transfer through the Depository Trust Company or another established clearing corporation and the Company is current
in payment of the fees to the Depository Trust Company (or such other established clearing corporation) in connection with such electronic
transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Application of Takeover Protections</U>. The Company and the Board have taken all necessary action, if any, in order to render
inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or
other similar anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents) or the laws
of its state of incorporation that is or could become applicable to the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(w)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Accuracy of Incorporated Documents</U>. The Incorporated Documents, when they were filed with the Commission, conformed in all
material respects to the requirements of the Exchange Act and the rules thereunder, and none of the Incorporated Documents, when they
were filed with the Commission, contained any untrue statement of a material fact or omitted to state a material fact necessary to make
the statements therein, in light of the circumstances under which they were made not misleading; and any further documents so filed and
incorporated by reference in the Registration Statement, the Base Prospectus, the Prospectus Supplement or the Prospectus, when such documents
are filed with the Commission, will conform in all material respects to the requirements of the Exchange Act and the rules thereunder,
as applicable, and will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
therein, in light of the circumstances under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Solvency</U>. Based on the consolidated financial condition of the Company as of the date hereof, (i) the fair saleable value
of the Company&rsquo;s assets exceeds the amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts
and other liabilities (including known contingent liabilities) as they mature, (ii) the Company&rsquo;s assets do not constitute unreasonably
small capital to carry on its business as now conducted and as proposed to be conducted including its capital needs taking into account
the particular capital requirements of the business conducted by the Company, consolidated and projected capital requirements and capital
availability thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would receive, were it to
liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or
in respect of its liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond its ability
to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt). The
Company has no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation under
the bankruptcy or reorganization laws of any jurisdiction within one year from the date hereof. The SEC Reports set forth as of the date
hereof all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary
has commitments. For the purposes of this Agreement, &ldquo;<U>Indebtedness</U>&rdquo; means (x) any liabilities for borrowed money or
amounts owed in excess of $50,000 (other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties,
endorsements and other contingent obligations in respect of indebtedness of others, whether or not the same are or should be reflected
in the Company&rsquo;s consolidated balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for
deposit or collection or similar transactions in the ordinary course of business; and (z) the present value of any lease payments in excess
of $50,000 due under leases required to be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with
respect to any Indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(y)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Tax Status</U>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result
in a Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income
and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has
paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns,
reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material taxes for
periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount
claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for
any such claim. The provisions for taxes payable, if any, shown on the financial statements filed with or as part of the Prospectus are
sufficient for all accrued and unpaid taxes, whether or not disputed, and for all periods to and including the dates of such consolidated
financial statements. The term &ldquo;taxes&rdquo; mean all federal, state, local, foreign, and other net income, gross income, gross
receipts, sales, use, ad valorem, transfer, franchise, profits, license, lease, service, service use, withholding, payroll, employment,
excise, severance, stamp, occupation, premium, property, windfall profits, customs, duties or other taxes, fees, assessments, or charges
of any kind whatsoever, together with any interest and any penalties, additions to tax, or additional amounts with respect thereto. The
term &ldquo;returns&rdquo; means all returns, declarations, reports, statements, and other documents required to be filed in respect to
taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(z)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Foreign Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary,
any agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful
payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate
funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf
of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of the Foreign Corrupt
Practices Act of 1977, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(aa)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Accountants</U>. The Company&rsquo;s accounting firm is set forth in the SEC Reports. To the knowledge and belief of the Company,
such accounting firm (i) is an independent registered public accounting firm as required by the Exchange Act and (ii) shall express its
opinion with respect to the financial statements to be included in the Company&rsquo;s Annual Report for the fiscal year ending March
31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(bb)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>FDA</U>. As to each product candidate of the Company subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;)
under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<U>FDCA</U>&rdquo;) that is manufactured,
packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product candidate,
a &ldquo;<U>Device</U>&rdquo;), such Device is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the
Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration, investigational
use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices,
product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would
not have a Material Adverse Effect. There is no pending, completed or, to the Company's knowledge, threatened, action (including any lawsuit,
arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its
Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the
FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses of,
the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Device, (ii)
withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales
promotional materials relating to, any Device, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its
Subsidiaries, (iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into
a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws,
rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have a Material
Adverse Effect. The properties, business and operations of the Company have been and are being conducted in all material respects in accordance
with all applicable laws, rules and regulations of the FDA.&nbsp; The Company has not been informed by the FDA that the FDA will prohibit
the marketing, sale, license or use in the United States of any product proposed to be developed, produced or marketed by the Company
nor has the FDA expressed any concern as to approving or clearing for marketing any product being developed or proposed to be developed
by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(cc)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Office of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director,
officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the
Office of Foreign Assets Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(dd)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>U.S. Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within
the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon the Manager&rsquo;s
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ee)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Bank Holding Company Act</U>. Neither the Company nor any of its Subsidiaries nor, to the knowledge of the Company, any of its
Affiliates is subject to the Bank Holding Company Act of 1956, as amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board
of Governors of the Federal Reserve System (the &ldquo;<U>Federal Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries
nor, to the knowledge of the Company, any of its Affiliates owns or controls, directly or indirectly, five percent (5%) or more of the
outstanding shares of any class of voting securities or twenty-five percent (25%) or more of the total equity of a bank or any entity
that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries nor, to the knowledge
of the Company, any of its Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is
subject to the BHCA and to regulation by the Federal Reserve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ff)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Money Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance
with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as
amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;<U>Money Laundering
Laws</U>&rdquo;), and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving
the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary,
threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(gg)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>FINRA Member Shareholders</U>. There are no affiliations with any FINRA member firm among the Company&rsquo;s officers, directors
or, to the knowledge of the Company, any five percent (5%) or greater stockholder of the Company, except as set forth in the Registration
Statement, the Base Prospectus, any Prospectus Supplement or the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(hh)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Environmental Laws</U>.&#9;The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign
laws relating to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface
or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants,
or toxic or hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) into the environment, or otherwise
relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials,
as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters,
orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<U>Environmental Laws</U>&rdquo;);
(ii) have received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective
businesses; and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i),
(ii) and (iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Ineligible Issuer</U>. (i)&nbsp;At the earliest time after the filing of the Registration Statement that the Company or another
offering participant made a bona fide offer (within the meaning of Rule&nbsp;164(h)(2)) of the Shares and (ii)&nbsp;as of the Execution
Time and on each such time this representation is repeated or deemed to be made (with such date being used as the determination date for
purposes of this clause&nbsp;(ii)), the Company was not and is not an Ineligible Issuer (as defined in Rule&nbsp;405), without taking
account of any determination by the Commission pursuant to Rule&nbsp;405 that it is not necessary that the Company be considered an Ineligible
Issuer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(jj)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Proceedings Related to Registration Statement</U>. To the knowledge of the Company, the Registration Statement is not the subject
of a pending proceeding or examination under Section&nbsp;8(d) or 8(e) of the Act, and the Company is not the subject of a pending proceeding
under Section&nbsp;8A of the Act in connection with the offering of the Shares. The Company has not received any notice that the Commission
has issued or intends to issue a stop-order with respect to the Registration Statement or that the Commission otherwise has suspended
or withdrawn the effectiveness of the Registration Statement, either temporarily or permanently, or intends or has threatened in writing
to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(kk)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Other Sales Agency Agreement</U>. The Company has not entered into any other sales agency agreements or other similar arrangements
with any agent or any other representative in respect of at the market offerings of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ll)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Regulation M Compliance</U>.&nbsp; The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly
or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company
to facilitate the sale or resale of any of the Shares, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases
of, any of the Shares, other than, compensation paid to the Manager in connection with the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Agreements</U>. The Company agrees with the Manager that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Right to Review Amendments and Supplements to Registration Statement and Prospectus</U>. During any period when the delivery
of a prospectus relating to the Shares is required (including in circumstances where such requirement may be satisfied pursuant to Rule&nbsp;172,
173 or any similar rule) to be delivered under the Act in connection with the offering or the sale of Shares, the Company will not file
any amendment to the Registration Statement or supplement (including any Prospectus Supplement) to the Base Prospectus unless the Company
has furnished to the Manager a copy for its review prior to filing and will not file any such proposed amendment or supplement to which
the Manager reasonably objects (provided, however, that the Company will have no obligation to provide the Manager any advance copy of
such filing or to provide the Manager an opportunity to object to such filing if the filing does not name the Manager and does not relate
to the transaction herein provided). The Company has properly completed the Prospectus, in a form approved by the Manager, and filed such
Prospectus, as amended at the Execution Time, with the Commission pursuant to the applicable paragraph of Rule&nbsp;424(b) by the Execution
Time and the Company will cause any supplement to the Prospectus to be properly completed, in a form approved by the Manager, and will
file such supplement with the Commission pursuant to the applicable paragraph of Rule&nbsp;424(b) within the time period prescribed thereby
and will provide evidence reasonably satisfactory to the Manager of such timely filing. The Company will promptly advise the Manager (i)&nbsp;when
the Prospectus, and any supplement thereto, shall have been filed (if required) with the Commission pursuant to Rule&nbsp;424(b), (ii)&nbsp;when,
during any period when the delivery of a prospectus (whether physically or through compliance with Rule&nbsp;172, 173 or any similar rule)
is required under the Act in connection with the offering or sale of the Shares, any amendment to the Registration Statement shall have
been filed or become effective (other than any annual report of the Company filed pursuant to Section 13(a) or 15(d) of the Exchange Act),
(iii)&nbsp;of any request by the Commission or its staff for any amendment of the Registration Statement, or for any supplement to the
Prospectus or for any additional information, (iv)&nbsp;of the issuance by the Commission of any stop order suspending the effectiveness
of the Registration Statement or of any notice objecting to its use or the institution or threatening of any proceeding for that purpose
and (v)&nbsp;of the receipt by the Company of any notification with respect to the suspension of the qualification of the Shares for sale
in any jurisdiction or the institution or threatening of any proceeding for such purpose. The Company will use its reasonable best efforts
to prevent the issuance of any such stop order or the occurrence of any such suspension or objection to the use of the Registration Statement
and, upon such issuance, occurrence or notice of objection, to obtain as soon as possible the withdrawal of such stop order or relief
from such occurrence or objection, including, if necessary, by filing an amendment to the Registration Statement or a new registration
statement and using its reasonable best efforts to have such amendment or new registration statement declared effective as soon as practicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Subsequent Events</U>. If, at any time on or after an Applicable Time but prior to the related Settlement Date, any event occurs
as a result of which the Registration Statement or Prospectus would include any untrue statement of a material fact or omit to state any
material fact necessary to make the statements therein in the light of the circumstances under which they were made or the circumstances
then prevailing not misleading, the Company will (i)&nbsp;notify promptly the Manager so that any use of the Registration Statement or
Prospectus may cease until such are amended or supplemented; (ii)&nbsp;amend or supplement the Registration Statement or Prospectus to
correct such statement or omission; and (iii)&nbsp;supply any amendment or supplement to the Manager in such quantities as the Manager
may reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notification of Subsequent Filings</U>. During any period when the delivery of a prospectus relating to the Shares is required
(including in circumstances where such requirement may be satisfied pursuant to Rule&nbsp;172, 173 or any similar rule) to be delivered
under the Act, any event occurs as a result of which the Prospectus as then supplemented would include any untrue statement of a material
fact or omit to state any material fact necessary to make the statements therein in the light of the circumstances under which they were
made not misleading, or if it shall be necessary to amend the Registration Statement, file a new registration statement or supplement
the Prospectus to comply with the Act or the Exchange Act or the respective rules thereunder, including in connection with use or delivery
of the Prospectus, the Company promptly will (i)&nbsp;notify the Manager of any such event, (ii)&nbsp;subject to Section 4(a), prepare
and file with the Commission an amendment or supplement or new registration statement which will correct such statement or omission or
effect such compliance, (iii)&nbsp;use its reasonable best efforts to have any amendment to the Registration Statement or new registration
statement declared effective as soon as practicable in order to avoid any disruption in use of the Prospectus and (iv)&nbsp;supply any
supplemented Prospectus to the Manager in such quantities as the Manager may reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Earnings Statements</U>. As soon as practicable, the Company will make generally available to its security holders and to the
Manager an earnings statement or statements of the Company and its Subsidiaries which will satisfy the provisions of Section&nbsp;11(a)
of the Act and Rule&nbsp;158. For the avoidance of doubt, the Company&rsquo;s compliance with the reporting requirements of the Exchange
Act shall be deemed to satisfy the requirements of this Section 4(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Delivery of Registration Statement</U>. Upon the request of the Manager, the Company will furnish to the Manager and counsel
for the Manager, without charge, signed copies of the Registration Statement (including exhibits thereto) and, so long as delivery of
a prospectus by the Manager or dealer may be required by the Act (including in circumstances where such requirement may be satisfied pursuant
to Rule&nbsp;172, 173 or any similar rule), as many copies of the Prospectus and each Issuer Free Writing Prospectus and any supplement
thereto as the Manager may reasonably request. The Company will pay the expenses of printing or other production of all documents relating
to the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Qualification of Shares</U>. The Company will arrange, if necessary, for the qualification of the Shares for sale under the
laws of such jurisdictions as the Manager may designate and will maintain such qualifications in effect so long as required for the distribution
of the Shares; provided that in no event shall the Company be obligated to qualify to do business in any jurisdiction where it is not
now so qualified or to take any action that would subject it to service of process in suits, other than those arising out of the offering
or sale of the Shares, in any jurisdiction where it is not now so subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Free Writing Prospectus</U>. The Company agrees that, unless it has or shall have obtained the prior written consent of the
Manager, the Company has not made and will not make any offer relating to the Shares that would constitute an Issuer Free Writing Prospectus
or that would otherwise constitute a &ldquo;free writing prospectus&rdquo; (as defined in Rule&nbsp;405) required to be filed by the Company
with the Commission or retained by the Company under Rule&nbsp;433. Any such free writing prospectus consented to by the Manager or the
Company is hereinafter referred to as a &ldquo;<U>Permitted Free Writing Prospectus</U>.&rdquo; The Company agrees that (i)&nbsp;it has
treated and will treat, as the case may be, each Permitted Free Writing Prospectus as an Issuer Free Writing Prospectus and (ii)&nbsp;it
has complied and will comply, as the case may be, with the requirements of Rules&nbsp;164 and 433 applicable to any Permitted Free Writing
Prospectus, including in respect of timely filing with the Commission, legending and record keeping.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Subsequent Equity Issuances</U>. The Company shall not deliver any Sales Notice hereunder (and any Sales Notice previously delivered
shall not apply during such three Business Days) for at least three (3) Business Days prior to any date on which the Company or any Subsidiary
offers, sells, issues, contracts to sell, contracts to issue or otherwise disposes of, directly or indirectly, any other shares of Common
Stock or any Common Stock Equivalents (other than the Shares), subject to Manager&rsquo;s right to waive this obligation, provided that,
without compliance with the foregoing obligation, the Company may issue and sell Common Stock pursuant to any employee equity plan, stock
ownership plan or dividend reinvestment plan of the Company in effect from time to time and the Company may issue Common Stock issuable
upon the conversion or exercise of Common Stock Equivalents outstanding from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Market Manipulation</U>. Until the termination of this Agreement, the Company will not take, directly or indirectly, any action
designed to or that would constitute or that might reasonably be expected to cause or result in, under the Exchange Act or otherwise,
stabilization or manipulation in violation of the Act, Exchange Act or the rules and regulations thereunder of the price of any security
of the Company to facilitate the sale or resale of the Shares or otherwise violate any provision of Regulation M under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notification of Incorrect Certificate</U>. The Company will, at any time during the term of this Agreement, as supplemented
from time to time, advise the Manager immediately after it shall have received notice or obtained knowledge thereof, of any information
or fact that would alter or affect any opinion, certificate, letter and other document provided to the Manager pursuant to Section&nbsp;6
herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Certification of Accuracy of Disclosure</U>. Upon commencement of the offering of the Shares under this Agreement (and upon
the recommencement of the offering of the Shares under this Agreement following the termination of a suspension of sales hereunder lasting
more than 30 Trading Days), and each time that (i) the Registration Statement or Prospectus shall be amended or supplemented, other than
by means of Incorporated Documents, (ii) the Company files its Annual Report on Form 10-K under the Exchange Act, (iii) the Company files
its quarterly reports on Form 10-Q under the Exchange Act, (iv) the Company files a Current Report on Form 8-K containing amended financial
information (other than information that is furnished and not filed), if the Manager reasonably determines that the information in such
Form 8-K is material, or (v) the Shares are delivered to the Manager as principal at the Time of Delivery pursuant to a Terms Agreement
(such commencement or recommencement date and each such date referred to in (i), (ii), (iii), (iv) and (v) above, a &ldquo;<U>Representation
Date</U>&rdquo;), unless waived by the Manager, the Company shall furnish or cause to be furnished to the Manager forthwith a certificate
dated and delivered on the Representation Date, in form reasonably satisfactory to the Manager to the effect that the statements contained
in the certificate referred to in Section 6 of this Agreement which were last furnished to the Manager are true and correct at the Representation
Date, as though made at and as of such date (except that such statements shall be deemed to relate to the Registration Statement and the
Prospectus as amended and supplemented to such date) or, in lieu of such certificate, a certificate of the same tenor as the certificate
referred to in said Section 6, modified as necessary to relate to the Registration Statement and the Prospectus as amended and supplemented
to the date of delivery of such certificate. Notwithstanding the foregoing, the requirement to provide a certificate under this Section
4(k) shall be waived for any Representation Date occurring at a time at which no Sales Notice is pending or a suspension is in effect,
which waiver shall continue until the earlier to occur of the date the Company delivers a Sales Notice hereunder (which for such calendar
quarter shall be considered a Representation Date) and the next occurring Representation Date on which the Company files its annual report
on Form 10-K. Notwithstanding the foregoing, (i) upon the delivery of the first Sales Notice hereunder and (ii) if the Company subsequently
decides to sell Shares following a Representation Date when the Company relied on such waiver and did not provide the Manager with a certificate
under this Section 4(k), then before the Manager sells any Shares, the Company shall provide the Manager with such a certificate, dated
the date of the Sales Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Bring Down Opinions; Negative Assurance</U>. At each Representation Date for which the Company is obligated to deliver a certification
pursuant to Section 4(k) for which no waiver is applicable, unless waived by the Manager, the Company shall furnish or cause to be furnished
forthwith to the Manager and to counsel to the Manager a written opinion of securities counsel to the Company and Nevada counsel to the
Company (collectively, &ldquo;<U>Company Counsel</U>&rdquo;) addressed to the Manager and dated and delivered on such date, in form and
substance reasonably satisfactory to the Manager, including a negative assurance representation from securities counsel to the Company,
at each Representation Date; <U>provided</U>, <U>however</U>, that the requirement for the Company to furnish or cause to be furnished
an opinion (but not with respect to a negative assurance representation) under this Section 4(l) shall be waived for any Representation
Date other than a Representation Date on which a material amendment to the Registration Statement or Prospectus is made or on which the
Company files its Annual Report on Form 10-K or a material amendment thereto under the Exchange Act, unless the Manager reasonably requests
such opinion required this Section 4(l) in connection with a Representation Date, upon which request such opinion shall be deliverable
hereunder. The Manager hereby agrees that Company Counsel may provide a reliance letter for a previously delivered opinion or negative
assurance representation, stating that such opinion or negative assurance representation may continue to be relied on, in lieu of providing
an opinion or negative assurance representation on any such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Auditor Bring Down &ldquo;Comfort&rdquo; Letter</U>. At each Representation Date for which the Company is obligated to deliver
a certification pursuant to Section 4(k) for which no waiver is applicable, unless waived by the Manager, the Company shall cause (1)&nbsp;the
Company&rsquo;s auditors (the &ldquo;<U>Accountants</U>&rdquo;), or other independent accountants satisfactory to the Manager forthwith
to furnish the Manager a letter, and (2)&nbsp;if requested by the Manager, the Chief Financial Officer of the Company forthwith to furnish
the Manager a certificate, in each case dated on such date, in form satisfactory to the Manager, of the same tenor as the letters and
certificate referred to in Section 6 of this Agreement but modified to relate to the Registration Statement and the Prospectus, as amended
and supplemented to the date of such letters and certificate, at each Representation Date; <U>provided</U>, <U>however</U>, that the requirement
for the Company to furnish or cause to be furnished a &ldquo;comfort&rdquo; letter under this Section 4(m) shall be waived for any Representation
Date other than a Representation Date on which a material amendment to the Registration Statement or Prospectus is made or on which the
Company files its Annual Report on Form 10-K or a material amendment thereto under the Exchange Act, unless the Manager reasonably requests
the deliverables required by this Section 4(m) in connection with a Representation Date, upon which request such deliverable shall be
deliverable hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Due Diligence Session</U>. Upon commencement of the offering of the Shares under this Agreement (and upon the recommencement
of the offering of the Shares under this Agreement following the termination of a suspension of sales hereunder lasting more than 30 Trading
Days), and at each Representation Date for which the Company is obligated to deliver a certification pursuant to Section 4(k) for which
no waiver is applicable, the Company will conduct a due diligence session, in form and substance, reasonably satisfactory to the Manager,
which shall include representatives of management and Accountants. The Company shall cooperate timely with any reasonable due diligence
request from or review conducted by the Manager or its agents from time to time in connection with the transactions contemplated by this
Agreement, including, without limitation, providing information and available documents and access to appropriate corporate officers and
the Company&rsquo;s agents during regular business hours, and timely furnishing or causing to be furnished such certificates, letters
and opinions from the Company, its officers and its agents, as the Manager may reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(o)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Acknowledgment of Trading</U>. The Company consents to the Manager trading in the Common Stock for the Manager&rsquo;s own account
and for the account of its clients at the same time as sales of the Shares occur pursuant to this Agreement or pursuant to a Terms Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(p)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Disclosure of Shares Sold</U>. The Company will disclose in its Annual Reports on Form&nbsp;10-K and Quarterly Reports on Form&nbsp;10-Q,
as applicable, the number of Shares sold through the Manager under this Agreement, the Net Proceeds to the Company and the compensation
paid by the Company with respect to sales of Shares pursuant to this Agreement during the relevant quarter; and, if required by any subsequent
change in Commission policy or request, more frequently by means of a Current Report on Form 8-K or a further Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(q)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Rescission Right</U>. If to the knowledge of the Company, the conditions set forth in Section 6 shall not have been satisfied
as of the applicable Settlement Date, the Company will offer to any person who has agreed to purchase Shares from the Company as the result
of an offer to purchase solicited by the Manager the right to refuse to purchase and pay for such Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(r)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Bring Down of Representations and Warranties</U>. Each acceptance by the Company of an offer to purchase the Shares hereunder,
and each execution and delivery by the Company of a Terms Agreement, shall be deemed to be an affirmation to the Manager that the representations
and warranties of the Company contained in or made pursuant to this Agreement are true and correct as of the date of such acceptance or
of such Terms Agreement as though made at and as of such date, and an undertaking that such representations and warranties will be true
and correct as of the Settlement Date for the Shares relating to such acceptance or as of the Time of Delivery relating to such sale,
as the case may be, as though made at and as of such date (except that such representations and warranties shall be deemed to relate to
the Registration Statement and the Prospectus as amended and supplemented relating to such Shares).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(s)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Reservation of Shares</U>. The Company shall ensure that there are at all times sufficient shares of Common Stock to provide
for the issuance, free of any preemptive rights, out of its authorized but unissued shares of Common Stock or shares of Common Stock held
in treasury, of the maximum aggregate number of Shares authorized for issuance by the Board pursuant to the terms of this Agreement. The
Company will use its commercially reasonable efforts to cause the Shares to be listed for trading on the Trading Market and to maintain
such listing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(t)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Obligation Under Exchange Act</U>. During any period when the delivery of a prospectus relating to the Shares is required (including
in circumstances where such requirement may be satisfied pursuant to Rule&nbsp;172, 173 or any similar rule) to be delivered under the
Act, the Company will file all documents required to be filed with the Commission pursuant to the Exchange Act within the time periods
required by the Exchange Act and the regulations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(u)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>DTC Facility</U>. The Company shall cooperate with Manager and use its reasonable efforts to permit the Shares to be eligible
for clearance and settlement through the facilities of DTC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Use of Proceeds</U>. The Company will apply the Net Proceeds from the sale of the Shares in the manner set forth in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(w)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Filing of Prospectus Supplement</U>. If any sales are made pursuant to this Agreement which are not made in &ldquo;at the market&rdquo;
offerings as defined in Rule 415, including, without limitation, any Placement pursuant to a Terms Agreement, the Company shall file a
Prospectus Supplement describing the terms of such transaction, the amount of Shares sold, the price thereof, the Manager&rsquo;s compensation,
and such other information as may be required pursuant to Rule 424 and Rule 430B, as applicable, within the time required by Rule 424.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Additional Registration Statement</U>. To the extent that the Registration Statement is not available for the sales of the Shares
as contemplated by this Agreement, the Company shall file a new registration statement with respect to any additional shares of Common
Stock necessary to complete such sales of the Shares and shall cause such registration statement to become effective as promptly as practicable.
After the effectiveness of any such registration statement, all references to &ldquo;<U>Registration Statement</U>&rdquo; included in
this Agreement shall be deemed to include such new registration statement, including all documents incorporated by reference therein pursuant
to Item&nbsp;12 of Form S-3, and all references to &ldquo;<U>Base Prospectus</U>&rdquo; included in this Agreement shall be deemed to
include the final form of prospectus, including all documents incorporated therein by reference, included in any such registration statement
at the time such registration statement became effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Payment of Expenses</U>. The Company agrees to pay the costs and expenses incident to the performance of its obligations under
this Agreement, whether or not the transactions contemplated hereby are consummated, including without limitation: (i)&nbsp;the preparation,
printing or reproduction and filing with the Commission of the Registration Statement (including financial statements and exhibits thereto),
the Prospectus and each Issuer Free Writing Prospectus, and each amendment or supplement to any of them; (ii)&nbsp;the printing (or reproduction)
and delivery (including postage, air freight charges and charges for counting and packaging) of such copies of the Registration Statement,
the Prospectus, and each Issuer Free Writing Prospectus, and all amendments or supplements to any of them, as may, in each case, be reasonably
requested for use in connection with the offering and sale of the Shares; (iii)&nbsp;the preparation, printing, authentication, issuance
and delivery of certificates for the Shares, including any stamp or transfer taxes in connection with the original issuance and sale of
the Shares; (iv)&nbsp;the printing (or reproduction) and delivery of this Agreement, any blue sky memorandum and all other agreements
or documents printed (or reproduced) and delivered in connection with the offering of the Shares; (v)&nbsp;the registration of the Shares
under the Exchange Act, if applicable, and the listing of the Shares on the Trading Market; (vi)&nbsp;any registration or qualification
of the Shares for offer and sale under the securities or blue sky laws of the several states (including filing fees and the reasonable
fees and expenses of counsel for the Manager relating to such registration and qualification); (vii)&nbsp;the transportation and other
expenses incurred by or on behalf of Company representatives in connection with presentations to prospective purchasers of the Shares;
(viii)&nbsp;the fees and expenses of the Company&rsquo;s accountants and the fees and expenses of counsel (including local and special
counsel) for the Company; (ix) the filing fee under FINRA Rule 5110; (x) not more than $50,000 in the aggregate for the reasonable fees
and expenses of the Manager&rsquo;s counsel; and (xi) all other costs and expenses incident to the performance by the Company of its obligations
hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Conditions to the Obligations of the Manager</U>. The obligations of the Manager under this Agreement and any Terms Agreement
shall be subject to (i)&nbsp;the accuracy of the representations and warranties on the part of the Company contained herein as of the
Execution Time, each Representation Date, and as of each Applicable Time, Settlement Date and Time of Delivery, (ii)&nbsp;the performance
by the Company of its obligations hereunder and (iii)&nbsp;the following additional conditions (except as set forth in Section 4(l) and
Section 4(m)):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Filing of Prospectus Supplement</U>. The Prospectus, and any supplement thereto, required by Rule&nbsp;424 to be filed with
the Commission shall have been filed in the manner and within the time period required by Rule&nbsp;424(b) with respect to any sale of
Shares; each Prospectus Supplement shall have been filed in the manner required by Rule&nbsp;424(b) within the time period required hereunder
and under the Act; any other material required to be filed by the Company pursuant to Rule&nbsp;433(d) under the Act, shall have been
filed with the Commission within the applicable time periods prescribed for such filings by Rule&nbsp;433; and no stop order suspending
the effectiveness of the Registration Statement or any notice objecting to its use shall have been issued, to the Company&rsquo;s knowledge,
and no proceedings for that purpose shall have been instituted or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Delivery of Opinion</U>. The Company shall have caused the Company Counsel to furnish to the Manager their respective opinions
and the negative assurance statement of securities counsel to the Company, each dated as of such date and addressed to the Manager in
form and substance reasonably acceptable to the Manager, which opinions and negative assurance statement shall be substantively identical
to those required under Section 4(l) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Delivery of Officer&rsquo;s Certificate</U>. The Company shall have furnished or caused to be furnished to the Manager a certificate
of the Company signed by the Chief Executive Officer or the President and the principal financial or accounting officer of the Company,
dated as of such date, to the effect that the signers of such certificate have carefully examined the Registration Statement, the Prospectus,
any Prospectus Supplement and any documents incorporated by reference therein and any supplements or amendments thereto and this Agreement
and that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the representations and warranties of the Company in this Agreement are true and correct on and as of such date with the same effect
as if made on such date and the Company has complied with all the agreements and satisfied all the conditions on its part to be performed
or satisfied at or prior to such date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>no stop order suspending the effectiveness of the Registration Statement or any notice objecting to its use has been issued and
no proceedings for that purpose have been instituted or, to the Company&rsquo;s knowledge, threatened; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>since the date of the most recent financial statements included in the Registration Statement, the Prospectus and the Incorporated
Documents, there has been no Material Adverse Effect on the condition (financial or otherwise), earnings, business or properties of the
Company and its subsidiaries, taken as a whole, whether or not arising from transactions in the ordinary course of business, except as
set forth in or contemplated in the Registration Statement and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Delivery of Accountants&rsquo; &ldquo;Comfort&rdquo; Letter</U>. The Company shall have requested and caused the Accountants
to have furnished to the Manager letters (which may refer to letters previously delivered to the Manager), dated as of such date, in form
and substance satisfactory to the Manager, confirming that they are independent accountants within the meaning of the Act and the Exchange
Act and the respective applicable rules and regulations adopted by the Commission thereunder and that they have performed a review of
any unaudited interim financial information of the Company included or incorporated by reference in the Registration Statement and the
Prospectus and provide customary &ldquo;comfort&rdquo; as to such review in form and substance satisfactory to the Manager.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Material Adverse Event</U>. Since the respective dates as of which information is disclosed in the Registration Statement,
the Prospectus and the Incorporated Documents, except as otherwise stated therein, there shall not have been (i)&nbsp;any change or decrease
in previously reported results specified in the letter or letters referred to in paragraph&nbsp;(d) of this Section 6 or (ii)&nbsp;any
change, or any development involving a prospective change, in or affecting the condition (financial or otherwise), earnings, business
or properties of the Company and its subsidiaries taken as a whole, whether or not arising from transactions in the ordinary course of
business, except as set forth in or contemplated in the Registration Statement, the Prospectus and the Incorporated Documents (exclusive
of any amendment or supplement thereto) the effect of which, in any case referred to in clause&nbsp;(i) or (ii)&nbsp;above, is, in the
sole judgment of the Manager, so material and adverse as to make it impractical or inadvisable to proceed with the offering or delivery
of the Shares as contemplated by the Registration Statement (exclusive of any amendment thereof), the Incorporated Documents and the Prospectus
(exclusive of any amendment or supplement thereto).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Payment of All Fees</U>. The Company shall have paid the required Commission filing fees relating to the Shares within the time
period required by Rule&nbsp;456(b)(1)(i) of the Act without regard to the proviso therein and otherwise in accordance with Rules&nbsp;456(b)
and 457(r) of the Act and, if applicable, shall have updated the &ldquo;Calculation of Registration Fee&rdquo; table in accordance with
Rule&nbsp;456(b)(1)(ii) either in a post-effective amendment to the Registration Statement or on the cover page&nbsp;of a prospectus filed
pursuant to Rule&nbsp;424(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No FINRA Objections</U>. FINRA shall not have raised any objection with respect to the fairness and reasonableness of the terms
and arrangements under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Shares Listed on Trading Market</U>. The Shares shall have been listed and admitted and authorized for trading on the Trading
Market, and satisfactory evidence of such actions shall have been provided to the Manager.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Other Assurances</U>. Prior to each Settlement Date and Time of Delivery, as applicable, the Company shall have furnished to
the Manager such further information, certificates and documents as the Manager may reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of the conditions specified
in this Section 6 shall not have been fulfilled when and as provided in this Agreement, or if any of the opinions and certificates mentioned
above or elsewhere in this Agreement shall not be reasonably satisfactory in form and substance to the Manager and counsel for the Manager,
this Agreement and all obligations of the Manager hereunder may be canceled at, or at any time prior to, any Settlement Date or Time of
Delivery, as applicable, by the Manager. Notice of such cancellation shall be given to the Company in writing or by telephone or facsimile
confirmed in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The documents required to
be delivered by this Section 6 shall be delivered to the office of Ellenoff Grossman &amp; Schole LLP, counsel for the Manager, at 1345
Avenue of the Americas, New York, New York 10105, email: capmkts@egsllp.com, on each such date as provided in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Indemnification and Contribution</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Indemnification by Company</U>. The Company agrees to indemnify and hold harmless the Manager, the directors, officers, employees
and agents of the Manager and each person who controls the Manager within the meaning of either the Act or the Exchange Act against any
and all losses, claims, damages or liabilities, joint or several, to which they or any of them may become subject under the Act, the Exchange
Act or other Federal or state statutory law or regulation, at common law or otherwise, insofar as such losses, claims, damages or liabilities
(or actions in respect thereof) arise out of or are based upon any untrue statement or alleged untrue statement of a material fact contained
in the Registration Statement for the registration of the Shares as originally filed or in any amendment thereof, or in the Base Prospectus,
any Prospectus Supplement, the Prospectus, any Issuer Free Writing Prospectus, or in any amendment thereof or supplement thereto, or arise
out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary
to make the statements therein not misleading or result from or relate to any breach of any of the representations, warranties, covenants
or agreements made by the Company in this Agreement, and agrees to reimburse each such indemnified party for any legal or other expenses
reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action; <U>provided</U>,
<U>however</U>, that the Company will not be liable in any such case to the extent that any such loss, claim, damage or liability arises
out of or is based upon any such untrue statement or alleged untrue statement or omission or alleged omission made therein in reliance
upon and in conformity with written information furnished to the Company by the Manager specifically for inclusion therein. This indemnity
agreement will be in addition to any liability that the Company may otherwise have.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Indemnification by Manager</U>. The Manager agrees to indemnify and hold harmless the Company, each of its directors, each of
its officers who signs the Registration Statement, and each person who controls the Company within the meaning of either the Act or the
Exchange Act, to the same extent as the foregoing indemnity from the Company to the Manager, but only with reference to written information
relating to the Manager furnished to the Company by the Manager specifically for inclusion in the documents referred to in the foregoing
indemnity; <U>provided</U>, <U>however</U>, that in no case shall the Manager be responsible for any amount in excess of the Broker Fee
applicable to the Shares and paid hereunder. This indemnity agreement will be in addition to any liability which the Manager may otherwise
have.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Indemnification Procedures</U>. Promptly after receipt by an indemnified party under this Section&nbsp;7 of notice of the commencement
of any action, such indemnified party will, if a claim in respect thereof is to be made against the indemnifying party under this Section&nbsp;7,
notify the indemnifying party in writing of the commencement thereof; but the failure so to notify the indemnifying party (i)&nbsp;will
not relieve it from liability under paragraph&nbsp;(a) or&nbsp;(b) above unless and to the extent it did not otherwise learn of such action
and such failure results in the forfeiture by the indemnifying party of substantial rights and defenses and (ii)&nbsp;will not, in any
event, relieve the indemnifying party from any obligations to any indemnified party other than the indemnification obligation provided
in paragraph&nbsp;(a) or (b)&nbsp;above. The indemnifying party shall be entitled to appoint counsel of the indemnifying party&rsquo;s
choice at the indemnifying party&rsquo;s expense to represent the indemnified party in any action for which indemnification is sought
(in which case the indemnifying party shall not thereafter be responsible for the fees and expenses of any separate counsel retained by
the indemnified party or parties except as set forth below); <U>provided</U>, <U>however</U>, that such counsel shall be reasonably satisfactory
to the indemnified party. Notwithstanding the indemnifying party&rsquo;s election to appoint counsel to represent the indemnified party
in an action, the indemnified party shall have the right to employ separate counsel (including local counsel), and the indemnifying party
shall bear the reasonable fees, costs and expenses of such separate counsel if (i)&nbsp;the use of counsel chosen by the indemnifying
party to represent the indemnified party would present such counsel with a conflict of interest, (ii)&nbsp;the actual or potential defendants
in, or targets of, any such action include both the indemnified party and the indemnifying party and the indemnified party shall have
reasonably concluded that there may be legal defenses available to it and/or other indemnified parties which are different from or additional
to those available to the indemnifying party, (iii)&nbsp;the indemnifying party shall not have employed counsel reasonably satisfactory
to the indemnified party to represent the indemnified party within a reasonable time after notice of the institution of such action or
(iv)&nbsp;the indemnifying party shall authorize the indemnified party to employ separate counsel at the expense of the indemnifying party.
An indemnifying party will not, without the prior written consent of the indemnified parties, settle or compromise or consent to the entry
of any judgment with respect to any pending or threatened claim, action, suit or proceeding in respect of which indemnification or contribution
may be sought hereunder (whether or not the indemnified parties are actual or potential parties to such claim or action) unless such settlement,
compromise or consent includes an unconditional release of each indemnified party from all liability arising out of such claim, action,
suit or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Contribution</U>. In the event that the indemnity provided in paragraph&nbsp;(a), (b)&nbsp;or (c)&nbsp;of this Section&nbsp;7
is unavailable to or insufficient to hold harmless an indemnified party for any reason, the Company and the Manager agree to contribute
to the aggregate losses, claims, damages and liabilities (including legal or other expenses reasonably incurred in connection with investigating
or defending the same) (collectively &ldquo;<U>Losses</U>&rdquo;) to which the Company and the Manager may be subject in such proportion
as is appropriate to reflect the relative benefits received by the Company on the one hand and by the Manager on the other from the offering
of the Shares; <U>provided</U>, <U>however</U>, that in no case shall the Manager be responsible for any amount in excess of the Broker
Fee applicable to the Shares and paid hereunder. If the allocation provided by the immediately preceding sentence is unavailable for any
reason, the Company and the Manager severally shall contribute in such proportion as is appropriate to reflect not only such relative
benefits but also the relative fault of the Company on the one hand and of the Manager on the other in connection with the statements
or omissions which resulted in such Losses as well as any other relevant equitable considerations. Benefits received by the Company shall
be deemed to be equal to the total net proceeds from the offering (before deducting expenses) received by it, and benefits received by
the Manager shall be deemed to be equal to the Broker Fee applicable to the Shares and paid hereunder as determined by this Agreement.
Relative fault shall be determined by reference to, among other things, whether any untrue or any alleged untrue statement of a material
fact or the omission or alleged omission to state a material fact relates to information provided by the Company on the one hand or the
Manager on the other, the intent of the parties and their relative knowledge, access to information and opportunity to correct or prevent
such untrue statement or omission. The Company and the Manager agree that it would not be just and equitable if contribution were determined
by pro rata allocation or any other method of allocation which does not take account of the equitable considerations referred to above.
Notwithstanding the provisions of this paragraph&nbsp;(d), no person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f)
of the Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. For purposes of
this Section&nbsp;7, each person who controls the Manager within the meaning of either the Act or the Exchange Act and each director,
officer, employee and agent of the Manager shall have the same rights to contribution as the Manager, and each person who controls the
Company within the meaning of either the Act or the Exchange Act, each officer of the Company who shall have signed the Registration Statement
and each director of the Company shall have the same rights to contribution as the Company, subject in each case to the applicable terms
and conditions of this paragraph&nbsp;(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company shall have the right, by giving written notice as hereinafter specified, to terminate the provisions of this Agreement
relating to the solicitation of offers to purchase the Shares in its sole discretion at any time upon five (5) Business Days&rsquo; prior
written notice. Any such termination shall be without liability of any party to any other party except that (i)&nbsp;with respect to any
pending sale, through the Manager for the Company, the obligations of the Company, including in respect of compensation of the Manager,
shall remain in full force and effect notwithstanding the termination and (ii)&nbsp;the provisions of Sections&nbsp;5, 7, 8, 9, 10, 12,
and 14 of this Agreement shall remain in full force and effect notwithstanding such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Manager shall have the right, by giving written notice as hereinafter specified, to terminate the provisions of this Agreement
relating to the solicitation of offers to purchase the Shares in its sole discretion at any time. Any such termination shall be without
liability of any party to any other party except that the provisions of Sections&nbsp;5, 7, 8, 9, 10, 12, and 14 of this Agreement shall
remain in full force and effect notwithstanding such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>This Agreement shall remain in full force and effect until such date that this Agreement is terminated pursuant to Sections&nbsp;8(a)
or (b)&nbsp;above or otherwise by mutual agreement of the parties, provided that any such termination by mutual agreement shall in all
cases be deemed to provide that Sections&nbsp;5, 7, 8, 9, 10, 12, and 14 shall remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Any termination of this Agreement shall be effective on the date specified in such notice of termination, provided that such termination
shall not be effective until the close of business on the date of receipt of such notice by the Manager or the Company, as the case may
be. If such termination shall occur prior to the Settlement Date or Time of Delivery for any sale of the Shares, such sale of the Shares
shall settle in accordance with the provisions of Section 2(b) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the case of any purchase of Shares by the Manager pursuant to a Terms Agreement, the obligations of the Manager pursuant to
such Terms Agreement shall be subject to termination, in the absolute discretion of the Manager, by prompt oral notice given to the Company
prior to the Time of Delivery relating to such Shares, if any, and confirmed promptly by facsimile or electronic mail, if since the time
of execution of the Terms Agreement and prior to such delivery and payment, (i)&nbsp;trading in the Common Stock shall have been suspended
by the Commission or the Trading Market or trading in securities generally on the Trading Market shall have been suspended or limited
or minimum prices shall have been established on such exchange, (ii)&nbsp;a banking moratorium shall have been declared either by Federal
or New York State authorities or (iii)&nbsp;there shall have occurred any outbreak or escalation of hostilities, declaration by the United
States of a national emergency or war, or other calamity or crisis the effect of which on financial markets is such as to make it, in
the sole judgment of the Manager, impractical or inadvisable to proceed with the offering or delivery of the Shares as contemplated by
the Prospectus (exclusive of any amendment or supplement thereto).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Representations and Indemnities to Survive</U>. The respective agreements, representations, warranties, indemnities and other
statements of the Company or its officers and of the Manager set forth in or made pursuant to this Agreement will remain in full force
and effect, regardless of any investigation made by the Manager or the Company or any of the officers, directors, employees, agents or
controlling persons referred to in Section&nbsp;7, and will survive delivery of and payment for the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notices</U>. All communications hereunder will be in writing and effective only on receipt, and will be mailed, delivered, e-mailed
or facsimiled to the addresses of the Company and the Manager, respectively, set forth on the signature page hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Successors</U>. This Agreement will inure to the benefit of and be binding upon the parties hereto and their respective successors
and the officers, directors, employees, agents and controlling persons referred to in Section&nbsp;7, and no other person will have any
right or obligation hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Fiduciary Duty</U>. The Company hereby acknowledges that (a)&nbsp;the purchase and sale of the Shares pursuant to this Agreement
is an arm&rsquo;s-length commercial transaction between the Company, on the one hand, and the Manager and any affiliate through which
it may be acting, on the other, (b)&nbsp;the Manager is acting solely as sales agent and/or principal in connection with the purchase
and sale of the Company&rsquo;s securities and not as a fiduciary of the Company and (c)&nbsp;the Company&rsquo;s engagement of the Manager
in connection with the offering and the process leading up to the offering is as independent contractors and not in any other capacity.
Furthermore, the Company agrees that it is solely responsible for making its own judgments in connection with the offering (irrespective
of whether the Manager has advised or is currently advising the Company on related or other matters). The Company agrees that it will
not claim that the Manager has rendered advisory services of any nature or respect, or owe an agency, fiduciary or similar duty to the
Company, in connection with such transaction or the process leading thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Integration</U>. This Agreement and any Terms Agreement supersede all prior agreements and understandings (whether written or
oral) between the Company and the Manager with respect to the subject matter hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Amendments; Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written
instrument signed, in the case of an amendment, by the Company and the Manager. No waiver of any default with respect to any provision,
condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default
or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right
hereunder in any manner impair the exercise of any such right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Applicable Law</U>. This Agreement and any Terms Agreement will be governed by and construed in accordance with the laws of
the State of New York applicable to contracts made and to be performed within the State of New&nbsp;York. Each of the Company and the
Manager: (i) agrees that any legal suit, action or proceeding arising out of or relating to this Agreement shall be instituted exclusively
in New York Supreme Court, County of New York, or in the United States District Court for the Southern District of New York, (ii) waives
any objection which it may have or hereafter to the venue of any such suit, action or proceeding, and (iii) irrevocably consents to the
jurisdiction of the New York Supreme Court, County of New York, and the United States District Court for the Southern District of New
York in any such suit, action or proceeding. Each of the Company and the Manager further agrees to accept and acknowledge service of any
and all process which may be served in any such suit, action or proceeding in the New York Supreme Court, County of New York, or in the
United States District Court for the Southern District of New York and agrees that service of process upon the Company mailed by certified
mail to the Company&rsquo;s address shall be deemed in every respect effective service of process upon the Company, in any such suit,
action or proceeding, and service of process upon the Manager mailed by certified mail to the Manager&rsquo;s address shall be deemed
in every respect effective service process upon the Manager, in any such suit, action or proceeding. If either party shall commence an
action or proceeding to enforce any provision of this Agreement, then the prevailing party in such action or proceeding shall be reimbursed
by the other party for its reasonable attorney&rsquo;s fees and other costs and expenses incurred with the investigation, preparation
and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>16.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Waiver of Jury Trial</U>. The Company hereby irrevocably waives, to the fullest extent permitted by applicable law, any and
all right to trial by jury in any legal proceeding arising out of or relating to this Agreement, any Terms Agreement or the transactions
contemplated hereby or thereby. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Counterparts</U>. This Agreement and any Terms Agreement may be signed in one or more counterparts, each of which shall constitute
an original and all of which together shall constitute one and the same agreement, which may be delivered by facsimile or in .pdf file
via e-mail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">***************************<BR STYLE="clear: both"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">18.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Headings</U>. The section headings used in this Agreement and any Terms Agreement are for convenience only and shall not affect
the construction hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the foregoing is in accordance
with your understanding of our agreement, please sign and return to us the enclosed duplicate hereof, whereupon this letter and your acceptance
shall represent a binding agreement among the Company and the Manager.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0">Very truly yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0"><B>AETHLON MEDICAL, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0">By: <U>/s/ James B. Frakes </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0">Name: James B. Frakes</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0">Title: Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0"><U>Address for Notice</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0">11555 Sorrento Valley Road,&nbsp;Suite 203</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0">San Diego, California 92121</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0">Attention: Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0">Email: jfrakes@aethlonmedical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0">The foregoing Agreement is hereby confirmed and accepted
as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0"><B>H.C. WAINWRIGHT &amp; CO., LLC</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 100%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0.5in; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0.5in; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0">By: <U>/s/ Edward D. Silvera</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0">Name: Edward D. Silvera</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0">Title: Chief Operating Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0.5in; text-align: justify">&nbsp;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0"><U>Address for Notice</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 100.1pt 0pt 0">430 Park Avenue<BR>
New York, New York 10022<BR>
Attention: Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 100.1pt 0pt 0">E-mail: notices@hcwco.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 100.1pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 100.1pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 100.1pt 0pt 0"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 100.1pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form of Terms Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ANNEX I </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AETHLON MEDICAL, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TERMS AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt">Dear Sirs:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 40pt">Aethlon
Medical, Inc. (the &ldquo;<U>Company</U>&rdquo;) proposes, subject to the terms and conditions stated herein and in the At The Market
Offering Agreement, dated March 24, 2022 (the &ldquo;<U>At The Market Offering Agreement</U>&rdquo;), between the Company and H.C. Wainwright
&amp; Co., LLC (&ldquo;<U>Manager</U>&rdquo;), to issue and sell to Manager the securities specified in the <U>Schedule&nbsp;I</U> hereto
(the &ldquo;<U>Purchased Shares</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 40pt">Each of
the provisions of the At The Market Offering Agreement not specifically related to the solicitation by the Manager, as agent of the Company,
of offers to purchase securities is incorporated herein by reference in its entirety, and shall be deemed to be part of this Terms Agreement
to the same extent as if such provisions had been set forth in full herein. Each of the representations and warranties set forth therein
shall be deemed to have been made at and as of the date of this Terms Agreement and the Time of Delivery, except that each representation
and warranty in Section&nbsp;3 of the At The Market Offering Agreement which makes reference to the Prospectus (as therein defined) shall
be deemed to be a representation and warranty as of the date of the At The Market Offering Agreement in relation to the Prospectus, and
also a representation and warranty as of the date of this Terms Agreement and the Time of Delivery in relation to the Prospectus as amended
and supplemented to relate to the Purchased Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 40pt">An amendment
to the Registration Statement (as defined in the At The Market Offering Agreement), or a supplement to the Prospectus, as the case may
be, relating to the Purchased Shares, in the form heretofore delivered to the Manager is now proposed to be filed with the Securities
and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 40pt">Subject
to the terms and conditions set forth herein and in the At The Market Offering Agreement which are incorporated herein by reference,
the Company agrees to issue and sell to the Manager and the latter agrees to purchase from the Company the number of shares of the Purchased
Shares at the time and place and at the purchase price set forth in the <U>Schedule&nbsp;I</U> hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 40pt"><FONT STYLE="font-weight: normal">If
the foregoing is in accordance with your understanding, please sign and return to us a counterpart hereof, whereupon this Terms Agreement,
including those provisions of the At The Market Offering Agreement incorporated herein by reference, shall constitute a binding agreement
between the Manager and the Company.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 19%; padding-left: 0.5in; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24%; padding-left: 0.5in; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 19%; padding-left: 0.5in; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 19%; padding-left: 0.5in; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 19%; padding-left: 0.5in; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="3">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0"><B>AETHLON MEDICAL, INC.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0">&nbsp;</P></TD>
    <TD STYLE="padding-left: 0.5in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="5">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By:__________________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Name:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Title:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0.5in">&nbsp;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0">ACCEPTED as of the date first written above.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 20%; padding-left: 0.5in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 20%; padding-left: 0.5in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 20%; padding-left: 0.5in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 20%; padding-left: 0.5in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 20%; padding-left: 0.5in; font-size: 10pt">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="3">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0"><B>H.C. WAINWRIGHT &amp; CO., LLC</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0"><BR>
    &nbsp;</P></TD>
    <TD STYLE="padding-left: 0.5in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By:__________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Name:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Title:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 99.75pt 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>aethlon_ex0501.htm
<DESCRIPTION>OPINION OF BROWNSTEIN HYATT FARBER SCHRECK, LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 5.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 60%"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 0.32in; width: 2.15in">&nbsp;</TD>
  <TD STYLE="width: 40%"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 9pt">Brownstein
                         Hyatt Farber Schreck, LLP&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 9pt">702.382.2101 main&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 9pt">100 North City Parkway, Suite 1600</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 9pt">Las Vegas, Nevada 89106&nbsp;</FONT></P>
</TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March 24, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon Medical, Inc.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">11555 Sorrento Valley Road, Suite 203<BR>
San Diego, California 92121</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the addressee set forth above:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have acted as local Nevada counsel to Aethlon
Medical, Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;), in connection with the transactions contemplated by that certain
At The Market Offering Agreement, dated as of March 24, 2022 (the &ldquo;<U>ATM Agreement</U>&rdquo;), by and between the Company and
H.C. Wainwright &amp; Co., LLC, as manager, relating to the issuance and sale by the Company of that number of shares (the &ldquo;<U>Shares</U>&rdquo;)
of the Company&rsquo;s common stock, par value $0.001 per share (the &ldquo;<U>Common Stock</U>&rdquo;) having an aggregate offering price
of up to $15,000,000, all as more fully described in the base prospectus, dated October 21, 2021 (the &ldquo;<U>Base Prospectus</U>&rdquo;),
contained in the Registration Statement on Form S-3 (File No. 333-259909) (as amended through and including the date hereof, the &ldquo;<U>Registration
Statement</U>&rdquo;), as supplemented by the prospectus supplement, dated March 24, 2022 (together with the Base Prospectus, the &ldquo;<U>Prospectus</U>&rdquo;),
each as filed with the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;) under the Securities Act of 1933, as amended.
This opinion letter is being delivered at your request pursuant to the requirements of Item 601(b)(5) of Regulation S-K under the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In our capacity as such counsel, we are familiar
with the proceedings taken and proposed to be taken by the Company in connection with the authorization, issuance and sale of the Shares
as contemplated by the ATM Agreement and as described in the Registration Statement and the Prospectus. For purposes of this opinion letter,
and except to the extent set forth in the opinion expressed below, we have assumed that all such proceedings have been or will be timely
completed in the manner presently proposed in the ATM Agreement and the Registration Statement and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For purposes of issuing this opinion letter, we
have made such legal and factual examinations and inquiries, including an examination of originals or copies certified or otherwise identified
to our satisfaction as being true copies of (i) the Registration Statement, including the Prospectus; (ii) the ATM Agreement, including
the form of Terms Agreement set forth therein (each, a &ldquo;<U>Terms Agreement</U>&rdquo;); (iii) the Company&rsquo;s articles of incorporation
and bylaws, each as amended to date (collectively, the &ldquo;<U>Governing Documents</U>&rdquo;); and (iv) such agreements, instruments,
corporate records (including resolutions of the board of directors and any committee thereof) and other documents, or forms thereof, as
we have deemed necessary or appropriate. For purposes of issuing this opinion letter, we have also obtained from officers and other representatives
and agents of the Company and from public officials, and have relied upon, such certificates, representations, assurances and public filings
as we have deemed necessary or appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Without limiting the generality of the foregoing,
we have, with your permission, assumed without independent verification that (i) the obligations of each party to any such document we
examined are or will be its valid and binding obligations, enforceable in accordance with its terms; (ii) each natural person executing
a document has, or when each Terms Agreement is signed will have, sufficient legal capacity to do so; (iii) all documents submitted to
us as originals are authentic, the signatures on all documents we reviewed are genuine, and any document submitted to us as certified,
conformed, photostatic, electronic or facsimile copies conform to the original document; (iv) all corporate records made available to
us by the Company, and all public records we have reviewed, are accurate and complete; (v) prior to any issuance of Shares, each Terms
Agreement with respect to such Shares will have been duly executed and delivered by the Company and the other parties thereto in accordance
with the ATM Agreement; and (vi) after the issuance of any Shares, the total number of issued and outstanding shares of Common Stock,
together with the total number of shares of Common Stock then reserved for issuance or obligated to be issued by the Company pursuant
to any agreement, plan, arrangement or otherwise, will not exceed the total number of shares of Common Stock then authorized under the
Company&rsquo;s articles of incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March 24, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are qualified to practice law in the State of
Nevada. The opinion set forth herein are expressly limited to and based exclusively on the general corporate laws of the State of Nevada,
and we do not purport to be experts on, or to express any opinion with respect to the applicability thereto or the effect thereon of,
the laws of any other jurisdiction. We express no opinion concerning, and we assume no responsibility as to laws or judicial decisions
related to, or any orders, consents or other authorizations or approvals as may be required by, any federal laws, rules or regulations,
including, without limitation, any federal securities laws, rules or regulations, or any state securities or &ldquo;blue sky&rdquo; laws,
rules or regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Based on the foregoing and in reliance thereon,
and having regard to legal considerations and other information that we deem relevant, we are of the opinion that the Shares have been
duly authorized by the Company and if, when and to the extent any Shares are issued and sold in accordance with all applicable terms and
conditions set forth in, and in the manner contemplated by, the ATM Agreement and any relevant Terms Agreement (including payment in full
of all consideration required therefor as prescribed thereunder), and as described in the Registration Statement and the Prospectus, such
Shares will be validly issued, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The opinion expressed herein is based upon the
applicable laws of the State of Nevada and the facts in existence on the date of this opinion letter. In delivering this opinion letter
to you, we disclaim any obligation to update or supplement the opinion set forth herein or to apprise you of any changes in any laws or
facts after the date hereof. No opinion is offered or implied as to any matter, and no inference may be drawn, beyond the strict scope
of the specific issues expressly addressed by the opinion set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We hereby consent to the filing of this opinion
letter as an exhibit to a Current Report on Form 8-K and to the reference to our firm in the Prospectus under the heading &ldquo;Legal
Matters&rdquo;. In giving this consent, we do not admit that we are within the category of persons whose consent is required under Section
7 of the Act or the rules and regulations of the Commission promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Very truly yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Brownstein Hyatt Farber Schreck, LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  F 0(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#X5^$OPOUK
MXT?$/1O!?AXVPUG57>.W^V2^7%E8VD.YL''RH>W6OIV3_@E+\>; >=;IX?EE
M3E1;ZJ5?/L60#]:\[_X)\R+%^V+\-F=E11=7&68X _T2:OW9DU>QAC9Y+VW1
M%&2S2J !]<UZ=:M*G)*)Y5"C&I%N1^&NG_&3]H;]B?XBQZ/J^J:SIEQ;!9'T
M+6KAKNPNH22,JI8H5."-\9!!!&017[*_ 3XP:=\>OA'X;\=:9$;:#5;?=):L
MVXV\R,4ECSWVNK ' R,' S7YJ_\ !5SXL^$_BQX^\">%?!MU;^)-:T=;E+RX
MTLB<;YVB$=NK)G>X,;$J,X+@=<BON_\ 89^$>K_!/]F;PGX<\01-;:VRS7UW
M:MUMWFD:01'_ &E4J&_V@U8UK2IJ;5F;T;QJ2@G='O=%?&_@[_@I3X9\1?M$
M7/PMU/PS-X?2'4[W2VUZZU&,P*\!D 9E*#:KF/'WN-PKBOB9_P %>O!/AGQ1
M-I7@_P (WWC&SAE\IM4EO!90RX."T2E'9E]"P7Z5A[&I>UCH]M3M>Y]^T5C>
M)?%^C^"_"]YXBU_4;?1]&LH?M%S>74@2.)?<^N2  .22 .37P-\3?^"Q'AG1
M]4FM/ W@B\\26T;;1J.IW?V))/\ :2,([$'MN*GV%3&G*?PHJ=2-/XF?HE17
MYS_#?_@L9X>U35(K7QOX$N]!M)&VG4-*O!>"//=HF1&P.^TD^@-??O@OQMH7
MQ$\,V'B+PUJEOK.BWT?F6]Y:ON1QT/N""""IP0000"*)TY0^)!"I&I\+-NBO
MA/4/^"J6D>'?C!-X#\0_#R^T:6TUK^Q[V_?5$=+?$WE/-M\L;E'+=>1WK[K9
M@JEB< <DFE*$HVNMQQJ1G?E8M%?,F@?MN6'BKQ]9^&=)\)W-VUY?"S@NOMJ@
M,I?:)"NS@8^8C/ KUSXV?%ZQ^"O@LZ_>VK7Y>X2VAM4D$9D=LD_-@XPJL>G:
MO<KY#F6&Q%+"U:5JE3X5=7?XZ?.QY%'.L!B*%3$TJEX4_B=GI^&ORN=_17D7
MP"_: 'QW35YK?P]-H]IIYC4SRW(E$CON^4 *.@7)^HKPC4?^"GGA7P]^T%?_
M  UUWPO-HUG8ZW-HUQXBN-13R(MDC1^<R;!A"0"<MP#GM7!BL!B<#7EAL1&T
MX[JZ=NO1L[,/CL/BZ,<11E>$MG9KRZH^U**_/;XN?\%?O"GAO6KC3O 7A&Y\
M6P0N4.JWUU]B@DQWC38SLONVP^U=)^S?_P %3O"GQ@\8:?X5\6^'W\$ZIJ$H
M@L[Q;L7-G+*QPL;,55HRQ( R",]2*Y?8U+7L;^WIM\MS[EHJ*ZNH;&UFN;F:
M.WMX4,DDTK!410,EF)X  &<FO@+XP?\ !7GP?X3URZTSP+X5N?&26[F,ZI=7
M7V.VD(.,QC8[NON0N:F-.4](HN=2-/63/T"HK\RO#O\ P6:)O%77_A=LM2>9
M=.U?<ZCV1X@#_P!]"OOCX&_&;0OC_P##/2O&_AR*\@TK4#(J0W\829&C=D=6
M"LPX93R"<TYTYPUDA0JPJ:19QW@[]M3X,^/O'5IX-T'QG'?^)+J=[:&R%A=(
M7D0,67>T07@*W4]J]NK^?;X5_%B#X&_M.6OCJYTV35X=&U:[F:RBE$32[A*F
M Q!Q]_/3M7ZN?LE?MW1_M8>-=5T/3O =WH-IIEC]LN=2GU!9D5BZJD>T1K\S
M98CGHAK:K0<-8[&-'$*>DMSZMHKSOXX?'SP7^SQX/;Q'XTU3[#:LWEVUK"OF
M7-W)C.R*/^(^IX ZD@5\&^(O^"S175'70?A?YNG*?EDU'5MDSCU*I$0I_P"!
M-6,*4YZQ1M.K"GI)GZ;5YW^T-XF\5^#?@CXSUOP18'4O%5CITDUA;K%YK%QC
M+!/XV5=S!<'<5 P<XKP[]F/_ (*.^ ?VA]>MO#-[9S^"_%ES\MM97TRRV]VW
M]R*8!<OZ*RJ3T&3Q7T!\:?B9%\&_A7XE\:SV#ZI%HMHUTUG'((VE (& Q!QU
M]#2Y91DDT/GC*+:9\@_\$R_CQ\8_C!>^,[?X@S7FM:!9I'):ZM?6JPM'<EB&
M@5E50X*Y8CG;M'3=7WG7R_\ LA?MR:?^UGKWB'2[+PE<^&VT>VCN6DGO5G$F
M]RN  BXZ9KG_ -J#_@HII7[,?Q4_X0N^\%7FNL+.&\:]M[](AMD+<!"AY&WU
MYK2<)3FTHV9E"<84TW*Z[GV!17P]\=/^"K?PZ^'%Z=,\%Z=-\0=050SW-O<"
MWL8R0"%$NUB[#/.U<=MV<XXCX6_\%A]#UOQ#;V'CKP1+X<TZ9PAU33;TW:P9
MXW/$45BH[E23Z*:7L:C5[%.O33M<_1BBJVFZE:ZQIUK?V-Q'>65U$L\%Q"P9
M)8V 974C@@@@@^]%8&Y_.]\ ?A+/\=?B]X<\"VVIQZ-/K$LD:WTD1E6+9$\F
M2H()SLQU[U]P/_P1HU\J<?%+3V/8'2),?^C:^8O^"?UU#9?M@?#B>XFCMX4N
MK@M),X15_P!%FZD\5^YDOCCPY!&TDFOZ7&B\EFO(P!^.ZO2KU)PDE$\S#TH3
MBW(_&7XC? ?XT?\ !.GQ9IOC73-2L)K.XD^R6^O6$*W$6XC<898YDS&S!3TZ
M@'#<&OTV_8M_:BB_:G^$O]NW-I%IWB/39_L.K6<!/EB7:&66/))".IR >00P
MR<9/S/\ \%1?VH/A_KWPA3X=>'==L/$WB"]U"&XN#ILRSQ64466RTBDKO8[5
M"@YP6)QQF[_P1S\&ZEI7PS\>>)+F)XM.UC4;>WM"X($AMTD\QE]1F8+GU4CM
M45/?I<\UJ73]RMR0>A\#>-/ -W\4_P!L3Q-X/L;B&TN]<\;7EA'<3YV1&2]=
M=S8Y(&<\>E?J[\.?^":_P,\#>'8+'4?"_P#PENH[ +C5-7GD+RMCDJB,$09Z
M #('4GK7YM> ?^4DEK_V4F;_ -.#U^Y=&(G*/*DPP\(RYFUU/RE_X*[?&G4;
MSQUX?^%MC</!HFFV::G?0HV!/<R%A&&]0D:Y'O*?05]$?L7?L"^ / /POT+Q
M#XS\.6/BKQEJ]K'?3G5X%N(;)9%#+#'$X*@JI&YB"2V<'&!7R=_P5R^'E_X?
M_: TGQ8T+'2O$&E1QQSX^7SX"4DC^H0Q-_P+VK]%_P!D/X^>'_CY\%/#NIZ7
M?0OJ]E90VFK:>''FVMRB!6W+U"L065NA!'<$!3;C1CR[#@E*M+FW/*_VNOV
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MO CYU!8;< ?,:_9GP#K5AX;^"?AK5M5NX;#3+'P_:W-S=7#!8X8DMU9G8GH
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MP,D!1V%?>OPW^+G[&7PK\)P>'M#UKPG]D2(1S3WFGM//='&"\TC1$N3[\=@
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M=M5T/C[_ ((T_P#)0/B/_P!@NU_]&M7FW_!6'_D[!O\ L!V?\Y*])_X(T_\
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+BBBO2YF>9R1/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>aemd-20220324.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +Kopo7xRiXgen8uEbXpMOa2P2aPty552mYkxvmR8fbnaLy8iRXwbeidKcFfWoScP -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:AEMD="http://aethlonmedical.com/20220324" elementFormDefault="qualified" targetNamespace="http://aethlonmedical.com/20220324">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://aethlonmedical.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="aemd-20220324_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="aemd-20220324_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>aemd-20220324_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>aemd-20220324_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.12c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://aethlonmedical.com/role/Cover" xlink:href="aemd-20220324.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140405156172376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Mar. 24, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 24,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AETHLON
MEDICAL, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000882291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3632859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11555
    Sorrento Valley Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite
    203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(619)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">941-0360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AEMD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>aethlon_i8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="aemd-20220324.xsd" xlink:type="simple"/>
    <context id="From2022-03-24to2022-03-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
        </entity>
        <period>
            <startDate>2022-03-24</startDate>
            <endDate>2022-03-24</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-03-24to2022-03-24">0000882291</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-03-24to2022-03-24">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-03-24to2022-03-24">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-03-24to2022-03-24">2022-03-24</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-03-24to2022-03-24">AETHLON MEDICAL, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-03-24to2022-03-24">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-03-24to2022-03-24">001-37487</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-03-24to2022-03-24">13-3632859</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-03-24to2022-03-24">11555     Sorrento Valley Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-03-24to2022-03-24">Suite     203</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-03-24to2022-03-24">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-03-24to2022-03-24">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-03-24to2022-03-24">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-03-24to2022-03-24">(619)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-03-24to2022-03-24">941-0360</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-03-24to2022-03-24">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-03-24to2022-03-24">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-03-24to2022-03-24">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-03-24to2022-03-24">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-03-24to2022-03-24">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-03-24to2022-03-24">AEMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-03-24to2022-03-24">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-03-24to2022-03-24">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( .^$>%0-#^-*[P   "L"   1              "  :\   !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( .^$>%297)PC$ 8  )PG   3
M      "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ [X1X
M5#3WCW59!   Y!   !@              ("!#@@  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( .^$>%2?H!OPL0(  .(,   -
M      "  9T,  !X;"]S='EL97,N>&UL4$L! A0#%     @ [X1X5)>*NQS
M    $P(   L              ( !>0\  %]R96QS+RYR96QS4$L! A0#%
M  @ [X1X5*K$(A8S 0  (@(   \              ( !8A   'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( .^$>%0D'INBK0   /@!   :
M  "  <(1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M .^$>%1ED'F2&0$  ,\#   3              "  :<2  !;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@     )  D /@(  /$3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="aethlon_i8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="aethlon_i8k.htm">aethlon_i8k.htm</File>
    <File>aemd-20220324.xsd</File>
    <File>aemd-20220324_lab.xml</File>
    <File>aemd-20220324_pre.xml</File>
    <File>aethlon_ex0101.htm</File>
    <File>aethlon_ex0501.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "aethlon_i8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "aethlon_i8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "aemd-20220324_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "aemd-20220324_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "aemd-20220324.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "AEMD",
   "nsuri": "http://aethlonmedical.com/20220324",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i8k.htm",
      "contextRef": "From2022-03-24to2022-03-24",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://aethlonmedical.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "aethlon_i8k.htm",
      "contextRef": "From2022-03-24to2022-03-24",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001683168-22-001925-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001683168-22-001925-xbrl.zip
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M>R_WY@7IUUBCWZA B-XKDO*5(7'L%FJ45WB9,.TA'[+'LB?=^.D72D#_ULQ
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MG-:*[%N]C2CD#%F?M!9FV+2>3G;9UBF\$^@)D861=%RDQDE_<H4.KL:>K6!
M"9+Y3H]C K0FX:BQE.5X\:5J'OR^A$DI&YO<DL76#F@8E[<&?-P=+;;Y'&4I
M3HMA7CLMS^6].>]/D_W%Z[OSNZCNS-8(PBV8PP&17!>P,W.T59A70[L$!:QT
MH'M$)XB1)1:^;@!7'3%&W77\9#H)RA]L21\*8;WMC/<F-@BB(7PV9-#N3]7]
MYAU>? 0+A^P[N4H&:D(X!O7 \DQ?<: IT^O1?VY8T]CYHS(Y.XDE<OR6YZ!W
M88!5<0K[@(\!GVZ'-=;=WC-2T>=;%+ IVT$,#&\YU'L=PC^DX,GI%YZD?8;
M<;TE5N^YL4CYH*SKSZNL(J_O!2;PRSDQ\CK,I&NF1#\9Y#K@<\'468JFV'%Q
M!9MA\.OI)"];[/EDH4JMTS97O>Z7KH?NBAH:4$:()H#C+/"==(.A6+-(A\=I
M/^Z0A"&'+-DH/4VR+,CM9X3:H_L/_DMO1C$.SDL: $9\WO5\AN"))HC&W?Z2
ML-G?$6L,S+&<UBB[E(GEGF#^M:5%-)W<(/&7W)0[\#(671MG>UV7NHRQ0<X"
MBO7ZCJ2Q-2_5P2%C2;22ZV;JFZN2?%SAYM!+<TLYX7(D#BRP:XG[%)3--M ?
M?NZ$I%N^)_U#9I(!*RTQ" !V#76JDS-KL2HRLKO09$N%\ALOGM.=R?8,&KZA
M9!6KY3WQ66M$8S:G657^VX%?U A"W+@/G&I]-/K.X,)O)6A9472+7S,. 2S5
M\'WG(9#&HAYA";MI;/GGI[3NI*\8>GMR=KH369P&EJ$9[T^)$H.D+K,%=3<L
M* (T$*0/I<;EDLZXWZ$$8<6.&0YZ2H./2Z\>C$)#?W(D<"L*M.@Z:60H&+<
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M(H\SV%I;NE9625RJVU)0?]N[1Q+<XJ)0$R/S070R2&:"@Y = $O";(&<KI1
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MX4HN/OXM7: :@&14;I"Q?(-QY%*B9-A@PHXUKDN;HYFR7$F=8CE,\#9HJMD
M !ICM$16;K3FAJIK!@H0;"51--<P+:N.R7G0* 0GNL[)YG(V<<K5/4/K)/U\
M<XYXY_V&OD.=<7T$T-668K$Q]4RTI$<F^)FG$CR/'F5"A[8]'04G.-8>Y-C(
MUK3A0WBU\,V0;[&'&9#D=C^%Y)HZ,*DQ!VR]Z7^RQ'4)6]=&!7PN9\@M:Y4<
M61(CCCE9(>_D'S=(&E0P]S!RZPCQH?0-Y"14JW]*\(D_8V=SP1DRN4 </AD'
M4Y!3' +9D)@8>JO:B:EY,%U3:)\2Q+PGQX\?AR$M[^58T76\KZXA@ $<,&*
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MLED$ZX>$,/)@<^>!NTIJ.>0VVB\ 'TQY*BQAX6CW*@MPE9B<%AM"AF6)K.-
MT#LPUY0XRB=4!1MXQ0IKIS0*8R^Q:!%FAKI]D3L44+PJ)\Z5N5MF1(<=M?/1
M>)X&S5@=%0LE;S&R*8>WCDR[_685:QY!1\OP9!2[GKE'1I%V.E/).K\6T4I*
MRK*&#\G/0SW-P6%Z+*E3[.$:)8D3X9)E.S-SQ"?EL.(DJS?PQ0.-! .I_^ L
MX.<9)[Z.<?/;G31N0*I\)O!*5Y"-491$.C[YG\RP"V)8GU;$(.VU#IZ-6*,B
MN#D%>3)?S:IN6ZW2+ML/_"^M,<[6"*)T'5LVS3;7#,8"IAEFB6O>K7?'89!K
MV-5%=9J=$HV/R^RD<#=JY><Z^J)'JV@WH==@?$++[R\I<I!BN->UE#E#*K*6
MR2H$W"()TK(+^+#9W\;05@5"@NK#J*EX$%S&D3-! <VF^X8/*<; NZY4GAI;
MKL(C"_:\?.Q6V5>'QY% @G;0L)RGK1FR+,%"" IH$5@$&SVJ/=7^F?=[<T?V
M^T 8R!(O_@M]45<5Q(+S4J%3UP.4&ZH,OT?JQNP>)(S<G6YGY_]JF)9_DL=Y
M7<G45K9*$X#E3!:@5ET&S2>&@''1O6:FN \-0G%]:)>X(:5^'BBXHQ-Q%#0/
MXP2XPKV")+_D_3WEF[!;4B=%B<](DQ=A:77C8+K(.2>(S4\:P;DO.3)2-RZJ
MAK0\KOB-\@&@!^*?D\*MFZ:^D >N82TNV<I%[TI!R/H%W\F;C.Q9$:T%1W=:
M\["@@LT66#4AG'$_W"<AZKAOFSL7!DOD/&UI\!#2T;[)#DX0!>,*KE,HJ=O=
MP,VHL5U1I"'+F2(V&^V"%\49\8^/"PE2_N_CAP_2!P\>))&489!1YHWI>;*5
M>*S4X'C5"0#<S=P2-T8@GPV22Y!K18B-IBC7<ZPL9>@TAPJB4E1$C!=GV6HY
M,,6(&B$8AO3)T\F;PTFU++N 5BFHK3-UDHR#V\4N/%B9%P/./Z^SY-8Q!L</
M#B"#6P 9'#\XH SN\-ZYCHG7WKJ)%Q ,9LT\ ]L[^>GCJN#8IH5Y[NG<]5'-
ME<^_F>+4B%A-LB0RA'L\!&D#^/#!@X<2 FP*V\]OJ#F?=&T;>>@@KQ<8*.OM
M"@,/00\?T^A06O+M/8@]9FL-GA-S5"7M)1SW:ZZR!K5 EI2A[W)%\*:3$H=Q
MD)/ Q'NPK%A<.1PH(VX#EG0:.N'DAUG%UM3>#]=$,Q#3B7"+D0TE)!\1;D1)
M+^(GH4O?Y$P+$'A\#,80?C.'4Q@)-FK?(@_$URP?4]7I-%(?;YDV+2<7A">2
MHK6,Z^?":S3D:0P4%JZ$.^[*R5">-0H(#T^&:1W+R R=@F!@9"?YL>"6(<H)
MT^17,X!\4=;9=28QP6ZM KHPR5)Q0."F' T<JES(RZ5P30Z$%H?3]V!<P9.Y
M%:0I'U'1Y'$01B6G,..,\A=+[1(5%,B]I4UX_"B[=_QD5G!K].,G.?]UY)R$
M*W/-N5(D,,K8C0H+:&7'1*/"\#X%(R31/]29\XHB>_%;A4L5PRQ8+<C$Q]LY
M08Q<7>!T$KPWU;NS.$@1=,O9M^T:SA+M$2>WMDD&K=E7BK> 42]45KY.RVDZ
MHGB]/YV8A?:\PX0&NV2'2QQ-7F^,_2I;9+]XL@O00\G8?/>I\8:2X>XZXE?A
M?PII*T64_")\>K>*9,9"0L%E6AJ?Z'K)[XI2\"(D-CD*MX?X_CSOOZ^_BM8T
M@6?3<L,49=(<6)%LCH&PW[,0<^2;$106EK:Y-[;3[^=A.L&)L-11T1QIY;!'
M9" '/=-4J5#J6>9(67 M@]@NS@^^Z,SRL^ V$<WA"(7LS!V-$2Z&)5Q<)$(9
M[PA"X]-^)LFP*C]0([:Z?[TD1O=_G3W&]YFYFM>Q:;M;MVE'ZY9@:Z&E\,H%
M)G_RP1$;3%(45-CSF(H[YTW]@6/<S-T">]O37!6%;^A"VIC-( 0U:>M.(>^Z
MNLI(CFI^7FKD+,O/RY9#6A*RR3"US&-),:ZQX% ,TDYTJ13N<PXRJSY07 S_
MX:.#DH\<XL&Y5HN=]WZNI-,T;4 D/7(]:8*G$#@%WU)G;LA8H:RQ$-,PZ5,0
M3;*OP(&JI81RLZ0#/SH<->D3&+4RCI.:6&>7TE9U"*9Q[7GX\V[M[:UO[9"V
MQF/D?D0OH."2K+?&L0P\5]MF%A1^V[DC,6JXZ4S.$6(K;-J\6PA\Z3''Y?'
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MDL0PWC*AOCF,P^T>I$=@O$PR'K)Y#6Z9YJA@WW7GXUW?B_V&<#1TU''ZRDT
M839I!O[$A]KYK1]J_:/MQ(-B40;>@VXF;^-G5]:[H_:".R$90!AN%A]^4Z:V
MDN!G:=#W@5-[*(*V68)FEVOIFL?=_IB,,K5DLNLY*5/B>*M+U  ;W.XSG\#C
MZ).A3Y7LG,/=Z@%ZE)@V=]I3"=3"O4[GPC>7&^\?:HK=.+IJ]R!M&$6NP'MU
MMN7-D;*:8;TU.>=,Y3IX)ZT:(9.<61L7V"3-3*+L7FDT]>?=31>WN)N"'81T
M$=F"X)6O;:>=%[K"?@,-?R_]63K7OX3#.X-$Q!*A=@UE?%<@TSZB%O.GWT\F
ML'/"%B0^]]#K)G/UN.&@OWK@?T#;F2#6C\4'?-2/-)/YI$8R41^9IR[I(RWD
M3*.EMG:-ABBB--9V20R[M]8^=<VUI,D<XBQ\B21_:$HF??\E51_V8@^G<X-C
M+N(="T3VDHC7CM8DOU>V8!S]SD7.5K.]*:\A(]<0D"24#Y*7WR<@O4Y#GY?.
MO7UPQ_$!W'$;X([C [CC#N^=ZYA"'^^@8_$.6WE5"ZD__-YDA<)^54.LY'%:
M8QA\(0TYJ*L6]5@E\Y<J26):3&>F2XX;T8L%=[ 2^'[BJZ,,$;J$Z*E'+C,>
ME)6+&H\\PN73\V*NC=[8NP@Z<7A/!4-<56(Z<YCKCJ1M(I$P(O]6K^E'_&I2
ME4V-!DIDDH*3RV>?II-V3=P<TL8!,?%9@[#,*L3$9TP/*=09DB_.VKB$VW_O
MW\>VB:AXFK,/#/_'0#NC$]A.0WAIN=B27R2_&+(L;!<1>5R8U4A#F9*4Y*]<
MR3-X9^YM1E_ $IUGX)L)7J*SX![?]T-YA5U#M#[#<:^'IC!I1.U A0^.XG4I
MFQ%DP4PGJQ)&2#(N95!EI^L*PUEV5+[>FTI&'H'T+,H-O?ZV]0EQ'&[J&?XC
M7$]VR3^6"A82<0H+&1G',5C)];:E*WQI!G?,2+,(BIS1=03:Y6T"O[FL)7OI
MJ#!EA,+L-N<2&[,9DMG0; B&04-U[MVD>XJ.CY-C0YL:QX"/.Y*6D6%<-@1Q
MDQ^0*<EY8#"RJ8@V(2_O<("2^KXRUKUN3K/*-9]&=<'2X (/O&<PH]9L-YWR
MO <_8S)O9;)KRC8O?= -XR_@TV&M9U1 :J%DMO37%U&$.AC)W;B!(,IIW)Q>
M=N"VTK]>5SB?13[ :S% 42OT/OMTB^=^,PO?AOY^\DJI(+8-*JIVJ#C65A[[
MD=DV,^L"NZG P9I8>M92 .I<5(!-*ZAN />,$[,+=LT-/OX)P^-M%087F(O$
MMDX:K]%0"5D,+X]H_D^W68/;G_K/PM:J!2%O&RS;OD\N0]K&@A\M$_<W)V^R
M,TR+Y$!EZT(SSNV9[Q]R57^F0$W/LQ5%T-NS N1L5@^TY?2=</Q;HNXWKXDC
MK8K3NBME#I5KDM9J.LDYC,TA,RY"Y_VE$;D@XWKUS', 8/;O(U'QW,O3%["B
MO%#=F,OS.W$@LT3E 7/ ALZCC56HG$X$UAKA']F[A"^D_61*@"CY;7?"9^;!
M7L=4OKR#IO+[[".%?[9A$=O2DU\FID_/GF7-N]M<>.XQVJJC1<Y]+I >_HG*
M@M 6/\M\4Q_?"C[L'CQ*-HK!LG719_;BSQE=B'CC,RS,ZF#"0#ML&P0$-X:F
M@ANJ94I1[7OP]L[#B(?6M:\E\_H,T^YD]!,)"3(&&5T:DKP2\9NQ*<] 1A45
MEC4>%$9[F X)I@XA%907G!?V8- MV222(>8WQ*TZ\HK>1#V3DL>L1:"V6O-U
M_:$UZ0LC"[!.OVV)8:]/G11$_OCM29,Z4*AOLBCA0-<16&<U> &W1/3&=OB;
MS<KU%,') O-J6]'$\V,E$N@&PQ,XG1!2)Y@T\0?@9V3X>>K=OBWD40F^\K-G
MD\COC Y%NX_.FEI:6-.<N%(\&A);4&["A9B*7D7.>)\-$R'@C3L(2#?!6L)P
MD[ND8S6QX*RA;C'.LB?$-YKUTK"1C3$_K;T373I5Y*FB>)7!3!>5R]W5P5,K
MT"?L[;$^W&.=9X90EV)]T5"LO<7[?HCP,?5LQ7X;5D4GVB%-3F$RVO OW#7@
M8FW0=<+@0"M<1!F13<#MUJG+NJ=>MQ!<FHL!A7TGY?/9,09YZB"Z'RX/UDU2
M03XL,C8-3 V3,3/8EWP#+%JG-G/P=NN-)4S&YQ;K<KMVG=RPEP>H^24MA8Z)
M"07@'_E6V["&M&94R6N4$EG3HI3(_" .E))*[K.NK7%(L>O*X'.I'M5LAZ,J
MPRE4_GXFA>::5/DP\^[D4,MZ\:FL((B:"$UO)M83_6&5AM,F:=!1W,N%3\=$
M!A5O)V/R$J<ESMN?V-[Y]QVT=U[)V?X<W"AP9$&529>(ZY#\<V.M*PJK!QN@
MD"43M,"5LG("+"!$::2&>,A7Q7,7C1_7:[2VG4=3;O[)V<(JY_-@6X&7OMRN
MI'A$\ DP[Z?EDHAF<>MA%BRLK->?^:)G0XBFYA*>L* #02(6R:9&EY7:>2"0
M7XN4CGS_5S\2/?U';N5-'CXS0;>3[C&$!HTZ$KN'0A$_ 2^#"LS@2N&=<LE2
M.$!PKK2B"NE]^"6U4@;FDC#SBA91A(<"=W<N&?F9>B4KMFCMR7*B]2>%V0]#
M8#7]!1RZ1Y[J,6;RAWE-F?;__$@II/*>.:.*B"L^U$H3H8MVR73BMHD6*QY_
M^_77U'$6G''8]OF?6(UEV:WHL0CG065U,=8W#,+[6LIER14FNXA(!JC"\""C
M2&&/P0!M/(RZ1H^07B=91?$;;$2'VS0 [V('U=[OLM!#&LS@D[I@@#UHG0;C
M0B7F-.I-6<40>]7%@Z:L]NJ1)N\CT:&3JD*F+^W:KJ0AL.WA4PI;"F7'CUF#
MM$R/CM/DX8.'#S\SP;_]C/O#0\;]-C+N#P\9]SN\=ZYS'LWGMWX>O7IQPN?0
M"5<;9TRB39T.%IB.L62;:KH8[FG\. B)R:74%NZ5<JB_:+:GR8GI,HQP5I\_
MD4%H$>MTXA&R0MU/MTKY/GC#YS4XIF@3<GV(,UY\5,:6JWC@6/C4Y\%C$T^F
M7FTQ'8=9IQ2MVL4'8LW#5D+%BCE:6PIT.&@PE477*W[^W\@VQ**#T:ZL0UW\
M9KXU8&\%T.$P":<7!88.PK8-]$/^@AI<%=SBS[Q*<ITW&7D1G\@<J7(88\S@
MZ<<Y3RQ9,:8:TY$J(]LURA:Z:(V@)* P][[EF$O!H^4" HZ1</R%0 ]U8]F;
MF87@'.-"Q/7OIXJXNGS/0?J6NDAQAY#XJ\4*Q)J\$O<%$8O1"DJ]1TKE+UDK
M,T^?4(OK#JQU_(,+[9,/1;'1G#,RU'%U;K-/]Y!>%T,*]%,ESU4<I!([Y<[H
MTH0XY5L57+WCR,=D]?_OB.E;VYJG6HX58>AQF;'3.N)'N>,9M_IJN(DWAWZ"
M)N1UT'W<=Q-))0XEX\,2&BZ/MB)QY)@W1_?>=!*V0(C!RGMLV)'N)VD";AVU
M(8'9ZTRG9THQ;RN5/TV>3R>@_\*^=T%R@!G=4M,<G8K"6H8E7RGUX<[A/4!R
M[[BI!>DA=>-!N8->$FX.HG1#5<+RR9?@B.S?&"ZE/UQA @N^XFK6M>WWPHHK
ME7X,J$WR!E$(!.6P T:EXMX=9C_#0"GWSF[U#=NB_#<UB^6G^[O5TH6/?ZV?
M,SF@V8YT#XSVTC[F@68^FQ%HIC0>/CI2:P8-9%XW8' WJ2NI$)8/QWJ47RVM
M%!$HJE_KDNF 4->03NL43,(PI+V%&6Y)=^R$PE(06D)!TC'_?(VG$$;IJ6)4
M&ALNB9DFHV;39?7KMMK-*#GX;(QQG"NE'K$FPK(6W,/ULM_=D Z-Z81/C;H)
M#HV]SUO!C..F L7*P<*K$Z(70SSUT\F 0@VHICTB#B/,\'%82.O!04I/00'S
MII!CW +D1B#U07)?*B:C\WC76:OAHA<G]]E('"HFU7Z34CLB4XW:R]5QXA\$
M28*W/RM!U;-280U%ZALWEDN+X"1+MP&R&H,TKZRV'J41:# OSHL53&6N#2&Y
MS'3$\ J[G^(H)10AJEN:1Q$VK!:-(YK 52,NW>WU6-.A\2JY$9D-U!NM)>SZ
M#$D<K^/>+!9WI+CJ)\K0HCQI.)3[0<$:4)G@=3(&^-%N:XAK!H4;%8._PI<J
M_!:&TA4)6YB&>"\J7]]QS#A@>!DY6VU6*9696%*&B6@ZN6H. L?M?4/T^WBN
M8:B=0O;&<_KIU<GS@'7HSRO#>7[K+CJMR-O"MEGX)Z>*,:JO19W]^EHII7=E
M[IBDE<.%5SEL%"7IYZ#LF_&>HL*+K!)_1+D;OOGV:]L.@MB&WF(+["V.@MMR
M'7_[S5?#'KJ+)E!D&!LN,)54XOIB"#F+I_83X^]/+&]%<4=TYO=(N>/EC)?J
M9-%=K2N'7*5J;_YJM7<-0[M'5NDMQ@;' O<D$+ADAK_PRNO[?T9A'R%F--T?
MY82FPG3*WOV#_+':8WPT+/666[TE[Y@1,WI4=%74A.AZ4T@&S+7FT)+<UQ>5
ME'LSWUHZFFI>HO,-&F%!.O_)?U%A^;IN]$DP'Q:IS00S8JDM5AEC?L_KSN&X
M2\W4=A=PR\M[X0,>]I\ [TAN[V];A5XERO^4.8)S[1K1%XU_2H1I<$FC%;DA
M08X+A<96H?@(KUV*9\@KL9+&.RL.XA-3@#C<PN5)QF2]0E16.S8;&KK$Y-[O
MF(T;TWV#&N^.:-CE\M;!+%;/_DC@_Q\RBH^",/AS?-Q-'$30$M%%E1L?TI1=
M22,\>KLA;AWC)5J&0/0G[]F8I"<-'*JP>DX&ZH('J&9FT'SCK?N]1Q\\2(F@
MRML'?BQ<&;%RDT/)X*UV[;B2)]G&_8/6<4FHI^,UF$Y^ %=YH"MRC<,6X/_/
M+B0I-&^<&!-O<MO0Q@U1OJ<X.:G%E6(52.[,?8V-<CBS7IW36';[!4/)\_A]
MDA\HE-9J;'>?;A*#H"<?Z/T3FV"GI[=N\K]Z_>;M2?(C-] @#A9NJN$Q(Q[J
MK#XD2;Q#7O(=I 4'(S5@,YT. B84P&S:/B%A])[&QJ#!<$IRTMB&(+T?%^-=
M=BRGQ71R%:D%CF)/4HO/3&QO'^/QZ(#QN V,QZ,#QN,.[YWKG"9G9[=^FKRL
MSLNF5BM$39O[?_U?WSY]?Y55B>G&L3X98X466O^!YM]T0L7$-I4/SLQJJU;4
MQC'$X?EPMH592,Z*;,75*JB\"S_Z(*N\GE.92E8VF/]KEAF."P\=*MT TT?^
M6!'<@"_@/@CP?G(]G3&9;4Z6](9;*#<R@22D" +SD%)P2<-4L\A\O$P69_!;
MF _L,$WOG%&1 ;$3(8TG_D4CZNJ/Y8)I,_^=-7F];;4)UT)XAK,6C=[(B/4&
M[#_=[S0E%5BO7-H>36;J\M*8<,/8FG_G,.5;./9_2N#8!+&4PW3X_GQ3./&1
M;IHNV]0MR@85R! 8DUZQRA77,#!L9G:Z*#!SQ?4;<>N.19T77,W1%/P/&&G.
M243^M^3=J1.7YB/ACU^W^:G4>6A_[512]JW4,&&$7'^,*Y/37;CS1DM<U56<
M<$R)=!?]%M+WDH[2]BP^WU[D(S"DX=VI2_>4NHT=28MT!S;@PJHULRI(KW '
M,]!\N8'FLNVU5OI"[SCUGRX=+BFOU44-OZ<3WWKTJ:D;W*$AL$9'BAJ5F<7%
MBQCK1.\19 1=PI^!+JYK'#B"< &HI%1FQ8T@C=$PU+\71G/I& YMW6+<GW>?
M4M@OL84OS.QMQTKZQ]GKRO'?OL:MU[!3!&+!UYY(ZXFL6958>T:M2(3WA(#@
MJGYB3\.SYR4]7N+:D>521J^0AHX-\Z54G93#@,U;9<F2JF?QJF1F>J*8# JV
ME.'1'G_U>'9V-'MXY+BOE;1;D/-\F>EZ0>V0R#%Z7TI1<RT[A)M2X*=$5M$4
M0BR0:8\=^*10O90CD87FIVGX,T^J2[!/3FMS\1$GSK74F&^82^GO=-+CR>"]
MRF/'MS@*:\ O,I^<<GFJI+>R<5L>/VV/'SPY2EW/769P<4VH5+^$H^TWRE)"
M<IR#X-:)LJO(V S_7RP83%^$]=+,6&)>8CKAM_@C%,0U=O&=T"2__GH'-8D/
MX6%DTI7!#>L$";U<%1+9H51$F @<QV%ZKJ5U83F/<J2RN(^9DUT^MR7ORB_R
MS2RG4,LWV))*1C'(EM]_;#+R5 5>A\\Y,7<?ZS?A5&*@PP89Z8<@D\D ^SVS
M\K!QQ2<R,CZ1>4(?8A\Z<$GO,1GT4!AT9!GJ9NAQ!GM&+ B$*,P1KV,0A*S'
M!YL:C=&P:GZI6&-6O2G9O'"0N=5E:E_.892<0X&-?#&'1I'@&HG9VOI/;'%\
M^'!'\M]O:NFV\PZ!H,D)Q>X]_5,?;J'B+6Z T(DY2"_A224%8%L!.ZO=L8;[
MWM>M9F=LK;&_I3W>SXN(ADD$7*#!NC_;:(-^$1F_U>H.GCUO?3;VQ[AUZ3@"
M,]5D;MC5!%L65<5@]3'^4E@ND5S?)_Y)L=G,/TE9KYE*LB"GJVX\V8\Z1RUW
MA_1<<S!_Y6;KL;H=H6 %=D8.'P,"8EPR:3;!+*-)Z>'CY'PRD%QSZEYZI1"=
MZV[F)<6<4C3J%F=9RUW34F;=Y)S<&C'B@KW'.! EU6G&]#=$;I$./<G3KJ7A
MG9@0)6B\-79(?IY[[AH[[?']N['/QO:<T]Y#W2CPN]8OEJXE-:;]3RFP.Z(P
M;Z=,_@I]2:3J9)V?E_#T$X0+>,8LG_1KQTUXNM(G UD(7G!-BY X8!-/[4<
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M-P#+Q&O;_ \AY?K<]MEMDBGU]]D+8VKNPIC_HOQ7FBL2^7!)V][^$\Q##_%
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M+8MRJ&OZ@3O:C/DR5(.SJ)%AGTY)KLARO;D,-5#P0IBS9)5#P4'*_%/3"9F
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MO;5.-99!F/ !O3 $MU>)B*D'&#?WZ4P=,)P,=Y]N.4=G2<:#7ZFE/4R'<CB
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M4RO;ALL#=$0P2LTS3"=!HH%P*P9[M'/&!TK[OPQO(K\[6RKR)@PMI.C&/=C
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MU4)9;V&W65U*A5S=:%JQESM+Y4N\0\3OM@LYWT/9T]VO8C#:,8[AM!L;=;@
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M2L,!K7D.C;@NVWPL[-*N !"=!8:EE!=&W9S!,DSKQJ=N55O?4@3RJH3S%\Y
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ME>A)"GTXD#:P>$E:^)]G@88K(17!;O2!0T/^+L7(9!3KI,*66'Q\8 IV* :
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MX?$O9\='O@\_$RNT#G?0[HLYS[WYKIO-TV8^;857P[Q0KZ6,+HM=E]MB8<?
M_0[QQ:4]9QSARQO$/L ?%^3Q\3Y\+OC-WG?1QRN,$;V.WB7JXMF@<5: QME[
M4#3.LK QLX7[^<''H__ ^?G\[=G[=V_^#U!+ P04    " #OA'A4H4'.X\ -
M   Y,   $@   &%E=&AL;VY?97@P-3 Q+FAT;=U;6V_;1A9^%Z#_,&NT@0W0
MLF37:6TK!GQ+8]1QC%A-T*?%B!Q)TU <9DA:5G_]?N?,#$G)=C=!T]TT =K8
MY,RYWP\S?#5Z?77<[0Q?79R<XV]!?X:CR]'5Q?%PQ_V-MSO^]?#TS?EOXG;T
MV]7%BXV)R<I#,>CGI1CIN2K$M5J(MV8NL\@]B,2MLGJR@8NX>A/NE>J^W):I
MGF:'PNKIK#P2<VFG&K_V-XZ'I\<7]S,]UJ78[PV&.Z>@XV8-0NOXLVQ<Y$?U
MD=')Z=6%.+NXNKHY.3^_O/[YQ49_@W^_O3DY"[][,&-C$V6W8Y.F,B_4H0@_
M'8E/Y>U(+'12SNAH_WMB=#AZ&\#?*5OJ6*:!U]+D1Z+-?*HFY08+?3@Z#[<\
MO.<$;GCY^F=Q^_;LQ8:>RZGZ=[\_Z/V>3S?$R=7HQ4;-QTR1%"&.WMZNSFJ2
M=GN#?9TU(AJ=/X'K!\9ULZK7L4F33Q) K0P<)?V]?',]:H/:+O0?D.U!#EY/
MK5ED1:ETYDWML3^OEK(LQ4MIQ\J*VWAF5?PA$M!H8(0P/&(5GZZSSR'YQ_YN
M;^^GW=[NH#_ 19W]7ZB >8EK8\N9.-/E4MQ(^V$AEP!5Z5*)P?-^?X6@OYN<
M*UF(=VHJ<?M:W<E$BI\.!OWGCXB&S0[_>^M^)O=\VID_Q]/_.H=?'.!K:>.9
MV/TA$KO]W=VOF=(O#O!$E;/49.*U2BCD1>(RBWM?',M@L+^_+VZ-M2HKC7@G
MTU0M<5,FP1-V^WO#4[*U6YF)<ZVF)A)G"+<38S,MQ<'N8'?P-<MQ9$0Y4T(F
MB55%H90H5(ED1(XOQ^9.'7Z]Q/O<IK-$99R,./F\5V(F[\!17*I$(&RD!O81
MHD9LJJQ0*5*C\!;4[:R84"1D<];FQLI2P\PV24C/TN1C98Z&OQZ?F7DNL^5P
MY]?C9Y8?;D5"9[B292KF&PL-$=*MTLJLD/RPH .EFN>I).+&2QR0I8B1MR5E
MJ!,( #?@UA^@A3>3";C.IN)D:I6:@\E()-)S929BU?O723P9O6XNKA(*O#(#
M>E4NE,J82,\0/>]V7O7.>N(]*%IPM22>R3D*B3/3HZ1X%A%ZZ ;U@8V$5>"%
MB"R=(>FBJ&06*\90R%0Y+AL,()R9SJHYI5O\6LPD;&^=_EM^VB:\V^&[-:AG
MMJ#G)-3Y'!(O2D-Y.Y=6W,FT4N*[?@\%C,B!AG$\HD6Z=TOWVHC(@(@E>+2<
M0H13"!V$>FWD5L>*::ERXOJ[P7[4[_?Y/X$ P>(QP#:ITG0I$E7$5H^A->U$
M/9:% A!3Y+"4J@@Z?1.7A@2R.V!]#M:)/:5K-_6U%8UV.V174%B#Y:V:ZJ+T
MUGM; @79@< O+XV=B]OM/;'Y4D,]UZ8G]O;VMG?W#P[Z!UMB$^1+G$T JYQ9
M4TUGK$N=Q6F5L*8!GF@6,V65F41BE= V9H3%@'K5!(&DJ/(\Y5?!%=IB:;T.
M$GI@[V8*%X;(:E=;D]$Z94]*3TD !DD3""1IP-VJN+*ZU#!.DL#%?3R3V93M
M;PX[?SPN^#<K]E1!FG8=Y$E<DO4/#O;V6!Y>Z+UN9S33</!<9X0A566)RW@R
M5B3]1*4:A3Y%@5(L367A@A\K590BKRSY7AE<D9YKRR+D>'$)1:#,'VR.MS;W
MM^@)5%6EWD2V?VF1"=IZ?W.<_I\D@\M,D(1BF<N8RE@V.^C:IX%(+!"HR%7E
M7*=:VFZG5CY,,5:*#+X0I?R .$DV@*>Y*<@U#/3A7ZQ%N"?R@*S*F;'Z#Y9W
M]$B@]-'-!;YN1SZ6+:":=ESGRSCX(,@\X?YTG%XWGM"C>$"F0VP5CH8'U@<7
MH9OJ/E9Y;5X0-X%LZ@6/.EQ5]SF7%)1H4K-@6;O,#,[G'%U@P10P625M>?.Q
M,>4F0]Z-(R1K*#]=4JB#1%39\ K3R&"WA T$(>362O(''HKL\T3T+7C"NI;)
M_%PP?ZAM:*K;81W,9:*<>E)DP92%,T$M4^%G=0^GR:2K:UR&H'BCB:XF6<BL
M?9 PPP= K$P+4FX,U""(*B ]T5 9GAD*Z@N-4*Z)!7[>[<#JR)4+P"DFKIPB
MRW=!L;1(]QX64&SJK3]1<;26RQI-'^&FO[IB,ZT;( 1O)Y1#@6BD[+QHV5;C
M#,0#2!.;E%NHJ&R2Q-JE=J9@ CP%ZU6.I.%.ZK67M8I3YYSC92H7$'W(974.
M-RY9;]*LB6+2';QH/3/^C$H?_0H$<F[BBC/&*EF$85/?;3ECD(%V5C4D[*YP
M'>+(HNR#GQ.4=8VPX: FK9S!^& W-M(F]$N"3(4*R#I3HC!*59V&/2HG2S/9
MXE=L'2()9$9D,:2.(ARC9(HX[H--0H0F M$8L4C:)1V7.44(JT'FP_#W7QS#
MA["T@#F.?<DUL8:L88*ZT-/OB+3*QR1)4B^<GE V^WR\5G<[,'DU3G7LH&F@
MB?@5(T6I31Y2Y90^7!IS;A.#D2):00<11QQH+>481Y0'C2*'@BPGF$^5TK<0
M =\C$9NJ%*F&607?AS*41;M>+H-&8$MHXO$^JHTH<DF<BRTT$[["B^I$MO"0
M"6&N&*NX([I(,V0^G.E"4#+0PE367L#^BIX%%,!5R198M<' .1:["$HE'VJ5
M5DK4,"2T.CIQ_1SP$U\M! @'&1B*E1RCP$ XDC%Y)=<=S!-!*"D>^=#'U"!6
MPVY2XK7@1(ZBM>38)QNZ9M+YWF*&-,W7UH,A_*?0TXP%!'J=)(N*+9O>NY12
MUV84J(PH3(B!5!G4;HY[8XX&%-"Z'?0'U /7F83D0O45I8O8!3="37R05V=K
MP!;D3'=:+;Q(807P>175L:?FLHU6.*QUKG)M%\4>_"SRF2E-0;X' A1%6FLR
M\F1+&;. T:5UBO+70B45^*C1'KE82T0_#*B<D^6=U"DKU8MCM0;UG."^=_IP
M.3A\8#]RHHO1E1 .NA7J*Q !&A  P(&WS+IFA=VZ,C5JJ;[;:73/QH7WE%?I
M-MNTN])8@ROQD@HEF[,QY0RY:7'6*NM0F[GP2DY#TN2X#QPKYMVJY%=2N4]E
M=V1@D]*W.VV^"$_@C<<WIH1FFFD%G?5TPN>A<.=T?HB! ^VI0D1URWJ7N@[Q
M\:MT-",1*GM'.<;8%IDV.'G=B7BRU@066D(NGUB"34F#MH)BF+74T[KA0*OV
MBIR:,E-RV:^2SR8]]#N4LD)CV>U\<E7S3>2<-23_VMX6+[5*DT-Q@SK@")#0
MND.C0"BVM_TZ='A^^6YU';%=FOQ0/,_KQ>7VV)2EF?MG?JT8GIVF$CH8@"J4
M6SK9./YB2\K6ZM%M+/V*AJ1%:#YW$_EP,[BW]_W*_O"1$S]\OPHJI@F2!;"6
M=(-<C\1HF8/ $RO'.CX2UZB*G>ROD6?>Y)PD#\4KG4!MI &/N@5J)\"BUT_1
MM+=&$\]-5QFAC5381PUWH.)'M#VV2G[8'BNJ00X1W\A$/L$"VKO4EE&VS6\%
M8YL[DH4SO2^SQ/M'.>T3:Z1_PH:.]?;E 'X],?)OVPI1H?.QHM6<=EDSMS1&
M@&.C<0ZC(AX2(!=U.VX)U..%3&@#F_;>=_<$T\^Y4,1P9^%@<STN:0:%[)E6
M!7?=PF3MIJ-5VU'K7L__/ E^#>5G;RC<4!U3.N9FU98^[P,[8BW5N%R-XZ&G
MA]-]('R]'.-Y9)ZC,D1<Y.XG%%'&541J,N&CW%+3V"9R@X] * /GLN;WRNH"
MSL,Y6[ROY0%::_2H=V,W7W"%Z2(, >D0D84HK#TAJ+!!AL-#T!/N@U$3QIJZ
M+E29O')B,3/+3 JE+!@$$!6NO?:ES.K4M:C[VCON&JB87I(4_:B<ZJ>( 4Y4
MPBIR,Q5;<85"'7T8F-.PHYYL1'4+R";@)[QM.$4S]_\3D(&=@DV@=0?/_;!F
M3(NMXL/2CV8<-,CD$7#?1 5URD[D':?NS?V\D4<B7!%[0_7.XO=WM+FS[(Z^
MU20S(WTT,TMG))K;L5:OOG C$8(/)Z1JV2\*O(\&P^;#S="^Z6JZ'6YK6C7P
M(ZV,GD2N?>:^9F6JWG0AC+;5=!3TF=0CG3QO'KU+4UO(S3BO<\%VHAW+[6%]
M%(38FJ&O+1RBIS8.H"Z(YD';WQKXY7+I)@$9+T-Y:>J:VI8B&N=C)5*C \>D
M&.)7&OR86XBMZ*\O/-SHK-MI-Z.( #Q&29=>TI%?WN;2SU8RDR%BT7 ,POTF
M'*N=UYI5C<]KM&UDQZ-AHVO<6K;U)]FJ%CB-Z M2CKJ'7KA^]DZ<^ N/#%A[
M*+]"]__$#)8[V:6IV",37<2IU'.7 ^JQ%\]J<H?'MA;)*Z[[()?[,0>R ZT>
M@"+D.;?U96;H5Y^:NAW'8C-%:.W$>^*ZR7[$ WT\X+8;&NZEW3<<OB='X.'A
MLK,S"D8X2P+SR2FQ<@$-C]72>.'"T)%P11&;7-5?19!]T\C1F7#1JDO"QSUU
M$'I*!M^$8;]W2A@O0S400JL;?*^;7K?C-^RT,R%S=9\"DV[$6<4??B&X<,45
M/I[X:?N7=LA&S/(*\SNJB<8A'Y>:P--:K\^4Y/CH<_H59:=NYS7;0>$S._O"
M5-_5?N"YB5JEH$SF1*K/6)0H*!5XS+05F!K+@VTWR46TFYE"U7(!T#KV.N)N
MW=*ZV_DQ^#=_I>"H=C4&,=XJ,EJ+C/!-!,JK>97ZX50=N_]AMK5Q_$Y!=J6E
M-$Z3_R+Z>K^$VSC>*79$\ZWSTU\T?\T\K '<H4__W;\%H'\R\!]02P,$%
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MZ=_?:Y?:RJ2SA(!$6<FG\KOYW/Y.\2E9P?^<Y>XLAI%AK>*-W/V6\ (8.E]
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M8HVN6M-FL"?*Q9R26]@=_^68>DF($9" !9E+!V3.;:J3^HBIOL<?&+GH04#
MW.W5B??YI %#"')D^\U"D'C$<V')FSG :0'L/__:SRE[!R[I,)W9 \L,8]HD
MY@JZC\'/YD;%850PI+3@;<*<$7T6=ENNQK5+_;MS;RK.WBH<9A0?2&Q7*6XO
M4=P%DD-W?V:!,ESBG!_+;%O?NA6UUAX/O[^^<C0E>QXGV%Q!@6Z[V;])=;M;
M;F8J:]HRVCJ&Q0BR[*:H^SHD^!@XGB3A/5(5.T@::>.BL[EQ1ETOV&GY?=7?
M7T]OJ@,&*Q=NEU$;UE[;X5AUZ%HCTF6Z-<2)8R/R@^RGOI >U\'."7<)QV.&
M&M,V-R 0=;GAZQXUF>6[^IBXD)ZYO;$8&HRPNC AF;4%^W/.M+;N R"'4',<
MMO4@X[&&. X# HYINDNV7,;("3.9 ^Z_8<)87VXQ5M*Y].:&('B[M$+FO,O<
M[SFI_F*^]B%N []'#:Z/2T\=T9OWBMG *UX[W ,=P$J*;P8IN;NDJ&Z<^*/C
M[,WQUU6$BTO/S\52A'(L[A4*!TO]9O C&@F4 U! 7A06L2,[W"T?U*&0VPG4
M=V[/&;>:MY0]4CUND5P^FX:.N '^]RI4_'YE+03*VH; 7 7)F/US\'#@YO1X
M3<U_=W*,-KO]N[LW5=5%>EZGIU,XH! 2T**2*@6:4G(1/9TY$#'1TD(V+7N^
M733[CYXNT=,PU+QT&+HO/&PKSB_A&NM AK,LZ!Q>MTYZ-^ZQ;KP^Y7N.OBZG
MZW5Z"_!2:@3@DXY6*6BIW%9W^WE:+/O^H\=KU^/C>#UNN*[/G">UF5;[CEY1
M]);+UZG-"]2M2Z?S+%784I^GTT'?->KTKP.,Q$,RW&<.I%!VW#%!8=M!^ ]S
M_]O&\6%]ZL4UQ^& >RR%4V+X_LS0H9'-_L*'I7EE!U\LD^<$U0%1=>JZRT\P
MA)-\8IOH25H#LA#.6]?P.PY%H:YKRZ ]-KJ6ON5N/UYU7C$C\VM@9#,X%"?T
MA 5^:EUL!1<!"@Z(IWYDAL'O[?S&(X=F J<X5G)=87M+EL+3/>M[H6'>=U9Q
M'GX>9Z*,ZQ\PM>U9ZEV2_#N;SF858E.'/%#=9\3&=Z[P_96U[:D\N^C^"&L#
M6Y<V&,_7:^/H_OBH6FU][J^ KS,(\43K>6U%I\)6QZP.K*C+=KM#O0C#CN5G
MA36MT\X]G'PQ6\K*MOS0B2SN]L71E #OXVKT?EGEODIM[D'J>TZ=.^;%[$"]
MZS"I8>(+TEAX'1-55&2APQTX/";.?LU52[E+0)8082*,/ND[UM ;;&Y L&EC
M"96Z1&,];LICRK)(E=TABV]%3%^&R),MG-/>@:Q4A;T!$4C Q@/.6!27(6NN
MF\K%  N%M;D1><=B"A8#V.G(".#TV\5YOPZP/LMC$K)XY=4IN=4:HCL1V*H2
M6;PU=G>LJEN_N#<[K_=BSTF4'B'LV3G2^Y5OHQ=C2:&4DV ^L6;)Y_<O-C<&
M8'1,AU0&C,ZT1&+CNTQT TF(?1(BKMK@(MF1+_JB  0R?8S8AQQPHW:90#VT
M..R!NS .3)F:*M;UJ"INH<#.>,^)1AW-E1LD6B2K$ALRT[>OMN@DK8KFENG7
M*_%$[.]>OBL'. $5N4GADO;9 ?2_]S'O![#R/@2Q8$>N-IB+Y(_F(WF)*04+
M>8GLXE'LX$$X8%>\BS/-7:.YZGPN.XMR,0F=2U87CI@^7DF:#31TUA,CYC,;
MD9)$CP@N]EB:E,[<4R'Y>D#P5<X2J3BTR]7PZ@KD?=,Z(!>VJ+"4R*FX% $E
M$*".@,J$L+!Y&4WY.9H<WA]XBV<=PW@B?+EZ0=H.HW>I+@,3!S)MH2+/D_!$
M22.J%]7D&8S1V2$OI.K]_8HFC]8W%256QY>]SYP-7GIK>,P@2CJKS+R %A>,
MOQQV'=_MP2UTBU 2;@"1&H9M7)QIJO0=)FJ(:3*/_B\2TUZ89/:ES"2IR.N
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ML7N6J?W8ZYU=W75#X6]N_#]02P$"% ,4    " #OA'A4^!%7:ST#   '#
M$0              @ $     865M9"TR,#(R,#,R-"YX<V102P$"% ,4
M" #OA'A4W[P]Q_\*  !LAP  %0              @ %L P  865M9"TR,#(R
M,#,R-%]L86(N>&UL4$L! A0#%     @ [X1X5",. C!9!P  S5@  !4
M         ( !G@X  &%E;60M,C R,C S,C1?<')E+GAM;%!+ 0(4 Q0    (
M .^$>%1.WF9TRY$  .91 P 2              "  2H6  !A971H;&]N7V5X
M,#$P,2YH=&U02P$"% ,4    " #OA'A4H4'.X\ -   Y,   $@
M    @ $EJ   865T:&QO;E]E># U,#$N:'1M4$L! A0#%     @ [X1X5*C7
M;'D^%@  :WP   \              ( !%;8  &%E=&AL;VY?:3AK+FAT;5!+
4!08     !@ & ((!  " S      !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
